UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
---------
FORM 10-K
Annual Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934 (Fee Required)
For the fiscal year
ended October 31, 1995 Commission File Number 0-19019
---------------- -------
PRIMEDEX HEALTH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
New York 13-33326724
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1516 Cotner Avenue
Los Angeles, California 90025
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (310) 478-7808
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.01
par value
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 of 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
Indicate by check mark if disclosure of delinquent files pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or in any amendment to
this Form 10-K.
The aggregate market value of the registrant's common stock held by
non-affiliates of the registrant was approximately $5,465,000 on December 29,
1995 based upon the mean between the closing bid and closing ask price for the
common stock in the over-the-counter market on said date.
The number of shares of the registrant's common stock outstanding on December
29, 1995 was 39,230,260 shares.
Documents Incorporated by Reference
The information required by Part III of this Report (Items 10, 11, 12 and 13) is
incorporated by reference from the registrant's proxy statement to be issued in
connection with its 1995 Annual Meeting of Stockholders or from an amendment on
Form 8 to this Report which proxy statement or amendment will be filed with the
Securities and Exchange Commission not later than 120 days after October 31,
1995.
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC.
PART I
Item 1. Business
(a) Primedex Health Systems, Inc. ("PHS" or the "Company") is a New York
corporation organized in 1985 and principally engaged through a wholly-owned
subsidiary, RadNet Management, Inc.
("RadNet"), in the healthcare services industry.
RadNet, acquired in June 1992 (as of April 30, 1992), directly and
through its wholly-owned RadNet Sub, Inc. subsidiary ("RadNet Sub"), owns and
operates 17 medical imaging centers and is a joint venture partner in two other
imaging centers. Four of the centers, comprising the Tower Division, which are
located in Beverly Hills and its environs, are owned and operated by RadNet Sub.
Thirteen of the imaging centers (including the four Tower Division centers) are
located in southern California with the remaining six centers located in
northern California. At the wholly-owned centers, RadNet provides the imaging
center facilities and equipment as well as all non-medical operational,
management, financial and administrative services. At the joint ventured
centers, RadNet performs non-medical management services. At all 19 centers, the
medical services and medical supervision are provided by various independent
physicians and physician groups (except that at seven of the Los Angeles area
centers, the medical services are provided by Beverly Radiology Medical Group
("BRMG"), a partnership of two physicians who are each beneficial owners of more
than 5% of the Company's common stock). One of the physicians is also chief
financial officer and a director of PHS and chairman of RadNet.). As
compensation for its management and other services at the various centers,
RadNet receives a management fee. In connection with the imaging centers in
which it is a joint venture partner, RadNet, in addition to a management fee,
also shares in joint venture net income after deduction of all expenses
including amounts paid for medical services and supervision. See "Item 1(c)
Narrative Description of Business - RadNet."
In December 1993, the Company purchased all of the outstanding capital
stock of Advantage Health Systems, Inc. ("AHS"), a newly organized corporation
formed to engage in providing medical/surgical utilization review services for
health insurers and other health service organizations. AHS subsequently was
merged into CareAdvantage Health Systems, Inc. ("CAHS"), a wholly-owned
subsidiary of CareAdvantage, Inc. ("CareAd"). CareAd was organized as a
wholly-owned subsidiary of PHS to acquire all of the issued and outstanding
common stock of CAHS. On October 28, 1994 pursuant to a planned separation of
PHS and CareAd, the PHS Board of Directors divested PHS of ownership of
approximately 96% of the outstanding CareAd common stock by declaration of a
dividend of 40,026,510 shares of CareAd common stock payable on a share for
share basis to the shareholders of PHS common stock. During fiscal 1995, the
Company made a number of cash advances to CareAd as capital contributions and in
April 1995, consummated a Separation Agreement with CareAd, in connection with
which, the Company's principal executive offices were moved from Newark, New
Jersey to Los Angeles, California, Robert T. Caruso resigned as president and
chief executive officer and Herman Rosenman was elected to succeed him. See
"Business - Developments Since the Beginning of the Last Fiscal Year."
On June 5, 1995, Howard G. Berger, an executive officer and a director of
the Company, chairman of RadNet and one of the two owners of BRMG, purchased
10,000,000 shares of the Company's common stock from the Company's then
principal stockholder, thereby becoming the Company's principal stockholder. See
"Business - Developments Since the Beginning of the Last Fiscal Year."
The Company's wholly-owned Primedex Corporation subsidiary ("Primedex")
acquired in February 1992, provided management, administrative and financial
services to four medical corporations (the "Medical Corporations") which
operated eight medical clinics in the greater Los Angeles area providing
medical/legal evaluation services and medical services to workers' compensation
claimants under the California workers' compensation system. Primedex provided
the Medical Corporations with the clinic facilities necessary for providing the
medical services and also provided management services and administration of all
of the non-medical functions and services relating to the operation of the
medical practice at the clinics in exchange for which Primedex was paid a
management fee based upon medical practice billings as received. Due to changes
in the California workers' compensation system including
1
<PAGE>
the enactment by the California State Legislature in July 1993 of new
legislation making significant changes to the system, the Company announced on
July 29, 1993 that Primedex would phase out its workers' compensation business.
At October 1, 1993, all eight medical clinics had been closed and at December
31, 1994, Primedex's work force had been reduced to approximately 55 employees
who were primarily engaged in collection of receivables. On August 4, 1995,
Primedex sold the bulk of its portfolio of receivables to an unaffiliated third
party. See "Business - Developments Since the Beginning of the Last Fiscal
Year."
In November 1995, the Company through a newly organized wholly-owned
subsidiary, RadNet Managed Imaging Services, Inc. ("RMIS") acquired the
outstanding capital stock of Future Diagnostics, Inc. ("FDI") enabling RMIS to
succeed to the bulk of FDI's business operations in California. FDI had been
arranging for the provision of imaging services for large payors (such as large
employers and insurance carriers) through an approximately 200 imaging center
network in California and had also been providing related utilization review and
quality assurance services. See "Business - Developments Since the Beginning of
the Last Fiscal Year."
The Company also owns a minority equity interest in Viromedics, Inc.
("VMI"), a privately owned New York based company holding certain residual
rights in the attempted development of a procedure to provide a composition for
preventing infection by the HIV virus (which causes Acquired Immune Deficiency
Syndrome ("AIDS")) or by the hepatitis virus.
As used herein, the term the "Company" includes PHS and its RadNet and
RMIS subsidiaries, as well as RadNet's RadNet Sub subsidiary and RMIS' FDI
subsidiary, unless the context otherwise requires. PHS' executive offices are
now located at 1516 Cotner Avenue, Los Angeles, California 90025 where its
telephone number is (310) 478-7808.
Developments Since the Beginning of the Last Fiscal Year
Effective November 1, 1994, RadNet acquired the remaining 50% joint
venture interest in the Lancaster Radiology Medical Group Joint Venture from its
joint venture partner, Lancaster Radiology Medical Group L.P. after such partner
executed its "buy-out" option requiring RadNet to make a cash "buy-out" of its
interest in the joint venture. The "buy-out" purchase price was $872,194 of
which $436,096 was paid upon closing, the balance being payable in 26
consecutive quarterly installments of principal in the amount of $16,773 through
December 1997 together with interest at the rate of 10% per annum.
Effective January 1, 1995, the Company settled the lawsuit brought
against RadNet by Antelope Valley MRI, L.P. ("Antelope Valley") concerning the
"buy-out" option previously granted to Antelope Valley by RadNet enabling
Antelope Valley to require RadNet to purchase the remaining 50% joint venture
interest in the Antelope Valley Imaging Joint Venture. In the lawsuit, Antelope
Valley contended that the correct "buy-out" price was not less than $2,787,545
and RadNet contended that the correct "buy-out" price was no more than
$1,355,000 assuming Antelope Valley's "buy-out" option was valid. In January
1995, the parties settled this lawsuit and agreed to a "buy-out" price of
$1,700,000 of which RadNet paid $400,000 upon closing. Of the $1,300,000
balance, an aggregate $300,000 was payable in four quarterly installments in
calendar 1995 with interest at the rate of 8% per annum and the balance is
payable commencing January 1, 1996 in 16 quarterly installments of principal
through October 1, 1999.
On January 4, 1995 (effective January 1, 1995), RadNet purchased all of
the assets of the Women's Diagnostic Imaging Center in Beverly Hills for a
$200,000 lump sum payment. All of the purchase price was paid to acquire the 50%
interest owned by a group of unrelated limited partners except for a nominal
amount ($1) paid to acquire the remaining 50% interest owned by Drs. Howard
Berger and Michael Krane, principal stockholders of the Company and the sole
partners of BRMG. After the purchase, the Women's Diagnostic Imaging Center was
merged into RadNet's Tower Division.
CareAd through its wholly-owned CAHS subsidiary is engaged in providing
health care cost containment services. These services include utilization review
and case management designed to enable health care insurers and other health
care service organizations to reduce the costs of medical services provided to
their subscribers without reducing the quality of service. To date, CareAd's
services have been provided to the statewide Blue Cross/Blue Shield health
service organizations of Rhode Island, Maine and New Jersey. CareAd management
advised that certain customers and potential vendors
2
<PAGE>
indicated that their contracts with CareAd would be dependent upon a separation
of CareAd from PHS. This position was based upon their concerns regarding the
pending criminal investigation being conducted by the Los Angeles District
Attorney's office, on the pending class action litigation against PHS (among
other defendants), and on a lawsuit initiated by the Securities and Exchange
Commission against PHS' then principal stockholder, Robert E. Brennan, alleging
violations of the federal securities laws in various matters unrelated to PHS or
CareAd. See "Item 3 - Legal Proceedings" herein.
In order to satisfy the requirements of CareAd's key customers and
vendors and to separate CareAd from PHS, the PHS Board of Directors on October
28, 1994, declared a dividend of 40,026,510 shares of CareAd Common Stock for
shareholders of record of PHS Common Stock at the close of business on November
7, 1994 (the "Dividend Record Date"). On October 31, 1994, a certificate for the
40,026,510 shares of CareAd Common Stock was deposited by PHS with Midlantic
Bank, N.A. as Deposit Agent to hold for the benefit of the holders of the PHS
Common Stock on the Dividend Record Date and for those subsequent transferees
who acquire such PHS Common Stock thereafter, until the Distribution of such
shares. Pursuant to the terms of the Deposit Agreement, the deposited CareAd
Common Stock was to be distributed upon registration of the shares under the
Securities Act of 1933 (the "Securities Act") or at such time as an applicable
exemption from registration became available, provided that if the Distribution
could not be effected, the Deposit Agent was required to dispose of the
deposited CareAd Common Stock for the benefit of the intended Distributees.
In February 1995, CareAd filed a registration statement on Form S-1 (File
No. 33-89176) with the Securities and Exchange Commission (the "Commission") to
register the shares to be distributed as a dividend. On June 12, 1995, the
registration statement was declared effective and the distribution of the
40,026,510 dividend shares was made promptly thereafter to the PHS stockholders
on the basis of one share of CareAd Common Stock being distributed for each
share of PHS common stock held. PHS retained an additional 1,700,000 shares of
CareAd Common Stock so that upon completion of the distribution, there were
41,726,510 shares of CareAd Common Stock outstanding.
CareAd, its wholly-owned CAHS subsidiary and CAHS' predecessor entity,
AHS, had relied on PHS for working capital and other required financial support
since the December 1993 acquisition by PHS of AHS through October 31, 1994. PHS
had agreed to make a total of $7,000,000 in working capital advances to CareAd
and its affiliated entities (of which $6,803,435 in cash advances had been made
at October 31, 1994) and had agreed to capitalize such advances. Since such
date, CareAd has been responsible for paying its own expenses. CareAd had also
relied on PHS for management and financial administrative assistance. On January
31, 1995, PHS and CareAd executed a separation agreement (the "First Separation
Agreement") hereinafter described concerning additional financial support to be
provided by PHS, the transfer of certain PHS senior management to CareAd and the
disposition of the 1,700,000 shares of CareAd Common Stock to be retained by PHS
after the Distribution.
Pursuant to the First Separation Agreement, PHS which had previously
agreed to capitalize its $7,000,000 of cash advances made to or in behalf of
CareAd, agreed to advance an additional $3,500,000 (the "Additional Cash
Payments") to CareAd as a capital contribution and further agreed to use its
best efforts to obtain a $3,000,000 credit line from a financial institution for
or provide such line of credit to CareAd to the extent required in connection
with a proposed joint venture transaction expected to be entered into by CareAd.
In consideration for PHS' agreements concerning the Additional Cash
Payments and the credit line, CareAd agreed to deliver releases to PHS from any
and all obligations (including contractual commitments, employment and option
agreements and guarantees) other than certain obligations of indemnification by
PHS, from four members of PHS, CareAd and CAHS' senior management, John J.
Petillo, Robert T. Caruso, Paul G. Shoffeitt and John T. Lincoln. To the extent
CareAd was unable to deliver such release from any of the four individuals, the
aggregate and monthly amounts of the Additional Advances as well as any excess
cash otherwise required to be applied to any unfunded amounts under the credit
line would be reduced in an amount equal to the additional amounts PHS was
required to pay to such individual subsequent to October 31, 1994 except that
with regard to Mr. Caruso, reductions would only be made for amounts paid to him
by PHS after he was relieved of his executive responsibilities at PHS.
3
<PAGE>
Concerning the 1,700,000 shares of CareAd Common Stock (the "Retained
Shares") retained by PHS after the Distribution, PHS agreed to file for a
registered exchange offer under the Securities Act with the Commission within
twelve months after the Distribution, offering the holders of the outstanding
PHS Debentures the right to exchange the Debentures for the Retained Shares. The
exchange package could also include other consideration. CareAd also agreed
within twelve months after the completion of the exchange offer and subject to
certain conditions, to file a registration statement under the Securities Act
with the Commission registering any of the Retained Shares not distributed in
the exchange offering (the "Remaining Shares") for public offer and sale by PHS
for PHS' own account, and PHS agreed to sell such shares at such time. PHS
agreed that CareAd's Board of Directors would hold all voting rights with
respect to the Retained Shares until transfer of any such shares pursuant to the
exchange offer, and thereafter, would continue to hold all voting rights with
respect to the Remaining Shares until public sale of such shares.
On April 24, 1995, PHS executed a second separation agreement (the
"Second Separation Agreement") with CareAd which modified the terms of the First
Separation Agreement. Pursuant to the Second Separation Agreement, in addition
to the approximately $7,000,000 of working capital advances it had made to
CareAd through October 31, 1994, PHS agreed to advance an additional $2,700,000
in cash payments (the "Additional Advances") to CareAd as a capital contribution
(instead of the $3,500,000 in Additional Cash Payments which it had agreed to
advance in the First Separation Agreement) and agreed to release CareAd from an
obligation to repay approximately $235,800 of certain other amounts advanced by
PHS. PHS paid $1,000,000 of the Additional Advances to CareAd on April 24, 1995
and agreed to pay the $1,700,000 balance on May 24, 1995 to the extent of
available funds, or if funds were unavailable to pay the $1,700,000 balance at
such time, to pay such balance in four consecutive monthly installments of
$425,000 without interest commencing on May 24, 1995. PHS agreed that if it did
not pay the entire $1,700,000 balance on May 24, 1995, it would provide CareAd
with a security interest in its Primedex subsidiary's workers' compensation
receivables to secure payment of the balance of the Additional Advances
(subordinated only to the right to one year of interest payments on a revolving
basis of the holders of PHS' outstanding 10% Series A Convertible Subordinated
Debentures due 2003 (the "PHS Debentures")). At April 28, 1995, annual interest
on the PHS Debentures aggregated $2,587,500. The Second Separation Agreement
also provided (in lieu of the requirement that PHS obtain a $3,000,000 line of
credit for CareAd), that in the event PHS or Primedex consummated a bank loan
for proceeds of at least $2,700,000 or consummated a sale of the bulk of
Primedex's workers' compensation receivables, any outstanding balance owed to
CareAd with respect to the Additional Advances would be paid by PMDX to CareAd
within five business days thereafter. The parties agreed that after payment of
the Additional Advances, no further capital contributions or advances would be
made by PHS to CareAd.
The Second Separation Agreement limited any requirement of PHS to pay the
$1,700,000 balance of the Additional Advances (even after a $2,700,000 bank loan
or a sale of the bulk of Primedex's workers' compensation receivables) unless
after paying such balance or any installment thereof, PHS together with its
Primedex subsidiary has in cash and/or cash equivalents, an amount equal to one
year of interest payments with respect to the outstanding PHS Debentures. The
Second Separation Agreement also provided that with respect to future monthly
collections of Primedex's workers' compensation receivables (expected to fund
the outstanding $1,700,000 balance of the Additional Advances), PHS after
deducting the direct costs of collection of same, was required to segregate in
each such month, an amount equal to 1/12 of the annual interest payable with
respect to the outstanding PHS Debentures prior to paying any balance of the
Additional Advances.
On July 24, 1995 at a time when PHS had paid $1,425,000 of the Additional
Advances leaving an outstanding balance of $1,275,000, CareAd accepted a
$1,000,000 lump sum payment from PHS in settlement of the balance.
In consideration for PHS' agreements concerning the Additional Advances,
CareAd agreed to deliver releases of PHS, its affiliated entities, its officers
and directors (the "Releasees") from any and all obligations (including
contractual commitments, employment and option agreements and guarantees) other
than certain obligations of indemnification by PHS, from the said four members
of PHS, CareAd and CAHS' senior management, namely John J. Petillo, Robert T.
Caruso, Paul G. Shoffeitt and John T. Lincoln and to the extent it was unable to
deliver any such release, to indemnify each of the Releasees from any and all
liabilities and damages attributable to claims asserted by any such individual
who failed to deliver such release at the April 24, 1995 Closing. At the
Closing, CareAd delivered the releases of
4
<PAGE>
Dr. Petillo and Mr. Caruso but as it was unable to obtain the required releases
from Dr. Shoffeitt (other than his previously delivered release of PHS from its
guarantee of the salary payable under his employment contract) and Mr. Lincoln,
it delivered an indemnification agreement with respect to any claims which Dr.
Shoffeitt and Mr. Lincoln might assert against the Releasees. The four
individuals had employment contracts directly with or guaranteed by PHS
providing for aggregate annual base compensation of $1,738,000, expiring at
various times in calendar years 1996 and 1997.
In connection with the April 1995 closing of the Second Separation
Agreement, Robert T. Caruso resigned as president, chief executive officer, a
director and an employee of PHS and was retained by PHS as a consultant for an
18-month term at a monthly consulting fee of $38,333. (In October 1995, PHS
bought out the balance of Mr. Caruso's consulting contract for a $455,000 lump
sum payment.) Herman Rosenman, president of RadNet, was elected at such time to
succeed Mr. Caruso as president and chief executive officer of PHS. Subsequent
to the closing of the Second Separation Agreement, during May 1995, Andrew C.
Alson, Roger Barnett, Roger A. Bodman and Peter W. Rodino, Jr. resigned as
directors of PHS. The three remaining directors at the time, Howard G. Berger,
Wilfredo Caraballo and Herman Rosenman, continue to serve as the sole directors
of PHS at the present time.
Concerning the 1,700,000 shares of CareAd Common Stock (the "Retained
Shares") to be retained by PHS after the Distribution, pursuant to the Second
Separation Agreement, PHS agreed to file for a registered exchange offer under
the Securities Act with the Commission within 18 months after the Distribution,
offering the holders of the PHS Debentures the right to exchange the Debentures
for the Retained Shares. The exchange package, which has not yet been
determined, may also include other consideration. CareAd has agreed within 18
months after the completion of the exchange offer and subject to certain
conditions, to file a registration statement under the Securities Act with the
Commission registering any of the Retained Shares not distributed in the
exchange offering (the "Remaining Shares") for public offer and sale by PHS for
PHS' own account, and PHS has agreed to sell such shares at such time. PHS
agreed that CareAd's Board of Directors will hold all voting rights with respect
to the Retained Shares until transfer of any such shares pursuant to the
exchange offer, and thereafter, will continue to hold all voting rights with
respect to the Remaining Shares until the earlier of public sale of such shares
or April 21, 2005.
On June 5, 1995, Howard G. Berger, chief financial officer and a director
of PHS and chairman of RadNet consummated the purchase of 10,000,000 shares of
PHS' common stock from Robert E. Brennan, PHS' then principal shareholder. In
connection with the purchase, John J. Petillo, the former chairman as well as
the former chief executive officer of PHS, waived his rights to vote the shares
pursuant to an irrevocable proxy previously granted by Mr. Brennan. The purchase
price for the shares was $.14 per share or $1,400,000 in the aggregate
consisting of (a) a $300,000 cash payment paid by Dr. Berger using personal
funds, (b) Dr. Berger's five-year 8% promissory note in the principal amount of
$700,000, and (c) the assignment by Dr. Berger of rights to receive 2,466,228
shares of CareAd Common Stock upon the Distribution of same. Mr. Brennan also
has the right to receive additional payments based upon future market prices for
PHS' common stock equal to 25% of the difference between the market price for
the shares sold and the initial $.14 purchase price per share, payable at
various times over a nine-year period. As Dr. Berger was granted the right to
make "additional payments" in cash or in shares of PHS' common stock (or
combinations thereof), Mr. Brennan was granted certain rights to register any
stock so transferred to him as additional payments under the Securities Act of
1933, at PHS' expense, so as to permit the public offer and sale of such shares.
As a result of the purchase, Dr. Berger is the beneficial owner of
12,747,478 shares representing approximately 32% of PHS' common stock. By virtue
of his stock ownership and the fact that he is a director and an executive
officer of PHS and chairman of RadNet, Dr. Berger may be deemed the controlling
person of PHS.
On August 4, 1995 (the "Closing Date") pursuant to a Medical
Receivables Purchase and Sale Agreement dated as of July 31, 1995 (the
"Agreement"), Primedex sold the bulk of its workers' compensation portfolio of
medical receivables (the "Portfolio") to an unaffiliated third party, Bristol
A/R Inc. ("Bristol") for a cash purchase price of $9,448,061 paid in full on the
Closing Date. The purchase price was established in arms-length negotiations
between management of both companies and represented 19% of the face amount of
the Portfolio of receivables being sold. At July 31, 1995 after allowances for
doubtful accounts, the net carrying value of the Portfolio as stated on
Primedex's financial statements was approximately $22,000,000. The sale was made
to Bristol without recourse to Primedex
5
<PAGE>
except in the event of breach of Primedex's representations and warranties
concerning the Portfolio made pursuant to the Agreement. The bulk of such
representations and warranties concerning the Portfolio were made "to the best
of Seller's knowledge after reasonable inquiry and investigation." Primedex
agreed to indemnify Bristol for any damages suffered based upon any
misrepresentation or breach of warranty concerning the Portfolio. However, with
respect to the pending investigations of Primedex's operations by the Los
Angeles District Attorney's Office and by other governmental agencies, such
indemnification is limited to damages arising from any indictment and conviction
for criminal violations of the matters under investigation. Primedex's
obligations to Bristol have been guaranteed by PHS and by RadNet.
In November 1995, RMIS acquired all of the outstanding capital stock of
FDI and thereby succeeded to the bulk of FDI's business operations in
California. FDI had been engaged in arranging for the provision of imaging
services for large payors (such as large employers and insurance carriers)
through an approximately 200 imaging center network in California and had also
been providing related utilization review and quality assurance services. The
assets acquired included an assignment of FDI's office space lease for the
premises at 6380 Wilshire Boulevard in Los Angeles, certain equipment and FDI's
diagnostic imaging contract network, including provider contracts, payor
contracts and all other assets utilized by FDI in the operation of its network.
In connection with the acquisition, RMIS assumed approximately $855,000 of FDI
liabilities and in addition agreed to pay an aggregate $2,345,000 to the
Sellers. RMIS paid $105,000 to the Sellers at the closing and an additional
$840,000 on January 2, 1996. The balance is payable in four quarterly
installments of $50,000 each over the first succeeding year, eight quarterly
installments of $75,000 each over the second and third succeeding years, four
quarterly installments of $100,000 each over the fourth succeeding year with a
final balloon payment of $200,000 on December 31, 1999.
At November 1, 1994, PHS owned 1,150,001 shares representing
approximately 19% of the outstanding common stock of ImmunoTherapeutics, Inc.
("ITI"), a publicly owned Minnesota based medical research company in the
development stage, engaged in research and development of certain compounds
intended to be used as immunopharmaceutical agents for the treatment of human
cancer. PHS had previously granted Gerald Vosika, the chief executive officer of
ITI, an option expiring on December 31, 2003 to purchase 575,000 of the ITI
shares owned by PHS at a purchase price of $3.00 per share and also granted Dr.
Vosika a proxy during the option term to vote such shares. On December 4, 1995,
PHS completed the sale back to ITI of said 1,150,001 shares of ITI common stock
at a sales price of $0.125 per share or $143,750.12 in the aggregate. PHS has no
present plans or intentions to purchase any additional shares of ITI common
stock.
During December 1995, PHS repurchased an aggregate 1,000,000 shares of
its outstanding common stock for an aggregate $321,720 in open market purchases
from unaffiliated third parties. In January 1996, PHS repurchased an additional
50,000 shares for $16,002 in similar transactions.
(b) Financial Information About Industry Segments
The Company is principally engaged in only one industry segment, the
healthcare services industry.
(c) Narrative Description of Business
General
Primedex Health Systems, Inc. ("PHS" or the "Company") is principally
engaged through a wholly-owned subsidiary, RadNet Management, Inc. ("RadNet"),
and through RadNet's wholly-owned subsidiary, RadNet Sub, Inc. ("RadNet Sub") in
the healthcare services industry in California. Substantially all of PHS'
operating revenues in fiscal 1995 are attributable to the operations of RadNet
(acquired as of April 30, 1992) and RadNet Sub. PHS through its wholly-owned
subsidiary, RadNet Managed Imaging Services, Inc. ("RMIS") has been engaged
since November 1995 in arranging for the provision of imaging services for large
payors and in providing related utilization review and quality assurance
services. PHS also owns approximately 4% of the outstanding capital stock of
CareAdvantage, Inc. ("CareAd"), the successor in interest through its CAHS'
subsidiary to the business of Advantage Health Systems, Inc. acquired in
December 1993. CAHS is currently engaged in providing medical/surgical
utilization review and case management services for health insurers and other
health service organizations. PHS also owns approximately 19% of the outstanding
stock of Viromedics, Inc.
6
<PAGE>
("VMI"), a privately owned New York based medical research company in the
development stage. PHS acquired its interests in VMI in November, 1990.
RADNET
RadNet, acquired in June 1992 (as of April 30, 1992), directly and
through RadNet Sub, owns and operates 17 medical imaging centers and is a joint
venture partner in two other imaging centers. Thirteen of the imaging centers
are located in southern California with the remaining six centers located in
northern California.
Medical Services
At its 17 wholly-owned imaging centers, RadNet supplies the imaging
center facilities and equipment as well as all non-medical operational,
management, financial and administrative services. At the joint ventured
centers, RadNet performs non-medical management services. At all 19 centers, the
medical services and medical supervision are provided by various independent
physicians and physician groups (except that at seven of the Los Angeles area
centers, the medical services are provided by an affiliated medical group,
BRMG). As compensation for its management and other services at the wholly-owned
centers, RadNet receives a management fee. In connection with the imaging
centers in which it is a joint venture partner, RadNet receives a management fee
and also shares in joint venture net income after deduction of all expenses
including amounts paid for medical services and supervision.
The following are the principal medical diagnostic procedures performed
on patients at the various imaging centers owned or managed by RadNet. The
patient is normally referred to the center for such diagnostic procedures by his
or her treatment physician who may be independent or may be affiliated with an
Independent Physician Association ("IPA"), a Health Maintenance Organization
("HMO"), a Preferred Provider Organization ("PPO"), or a similar organization
who has contracted for such services. See "Marketing" herein. Not all of such
procedures are performed at each center.
Computed Axial Tomography (CT) - CT is 100 times more sensitive than
conventional x-ray. It is used to see inside any of the body's organs, including
the brain, to detect disease and damage. CT focuses an x-ray on a specific plane
of the body, processes the image by computer, and constructs a picture on a
monitor, and later on film. Tissues of various density appear as different
shades of gray, bone (the most dense) as white, and air and fluid as black. The
procedure is painless and takes about one-half hour per study; more than one
study is often ordered on each patient. The patient simply lies on a special,
monitored table which is guided into the scanner. Some CT studies involve the
use of an injected contrast agent to better visualize anatomy and pathology.
RadNet primarily uses non-ionic CT contrast agents to minimize contrast
reactions. A CT system costs in the range of approximately $500,000 to
$1,000,000.
Diagnostic Radiology - X-ray services; diagnostic tests employing x-ray
radiation on two planes; includes fluoroscopy and endoscopy.
Magnetic Resonance Imaging (MRI) - Diagnostic imaging based on magnetism
rather than radiation or conventional x-ray. MRI has become widely accepted as
the standard diagnostic tool for a wide and fast-growing variety of clinical
applications: MRI is painless, requiring only that the patient lie still on a
motorized table that slides into a long cylinder. On some MRI studies, an
injected contrast agent is used, and some require the use of special "coils,"
permitting highly accurate scanning of a particular part of the body. MRIs are
the most expensive pieces of equipment at RadNet imaging centers costing between
$1,500,000 and $2,000,0000.
Mammography - Provides an x-ray picture of the breast, and is used to
detect tumors and cysts, and to help differentiate between benign and malignant
tumors.
7
<PAGE>
Nuclear Medicine - Involves the use of a small amount of radioactive
material and is used to obtain information about the anatomy and functioning of
various organs. Nuclear medicine is based on the principle that organs absorb or
concentrate scientific minerals or hormones. These substances are not visualized
on conventional x-ray, but if they are made radioactive by the addition of a
radioisotope, they can be seen. If an organ is not functioning properly, too
little or too much of the substance will be taken up or concentrated in some
parts of the organ, but not other parts. The organ will thus appear different on
a screen. The amount of radiation is extremely low, and the isotope usually
disappears from the body within a day or less.
Ultrasound - A painless imaging technique that uses sound waves and their
echoes to visualize and locate internal organs. It is particularly useful in
looking at soft tissue that does not x-ray well. Ultrasound is used in pregnancy
to avoid x-ray exposure as well as in gynecological, urologic, vascular, cardiac
and breast applications.
Imaging Centers
All of the imaging centers owned or managed by RadNet are located in
leased facilities with the exception of the La Habra joint venture imaging
center where the joint venture owns the building in which the center is located,
subject to a land lease, and the Northridge imaging center where RadNet owns the
building and the land. Certain information with respect to RadNet's imaging
centers is as follows:
<TABLE>
<CAPTION>
RadNet's
Annual Percentage
Date of Rental Interest in
Acquisition Approximate for Profits from
of RadNet Square Feet Leased Non-Medical
Center - Wholly-Owned Interest of Center Facility Services
<S> <C> <C> <C> <C>
Tower Division:
(Beverly Hills and Environs)
Roxsan 1984 8,143 $ 205,000 100%
120 East 1994 5,350 $ 277,000 100%
444 San Vicente 1994 9,900 $ 641,000 100%
1 West/Women's 1994 4,600 $ 290,000 100%
Antelope Valley 1992 2,900 $ 66,200 100%
Lancaster 1992 3,327 $ 106,000 100%
Northridge 1990 7,500 $ -- 100%
Orange 1994 4,200 $ 114,000 100%
Sacramento (DRI)(a) 1993 9,771 $ 291,000 100%
San Francisco 1993 3,380 $ 105,000 100%
Santa Clarita 1992 4,833 $ 67,000 100%
Santa Rosa 1992 5,500 $ 135,000 100%
Stockton/Valley 1993 6,800 $ 138,000 100%
Tustin 1993 5,300 $ 96,000 100%
Vacaville 1993 1,743 $ 36,000 100%
Ventura 1992 9,440 $ 125,000 100%
Joint Ventures
La Habra 1988 2,500 $ -- 50%
Westchester 1991 6,763 $ 200,000 50%
Other Facilities
RadNet
(Corp. office) 1990 11,500 $ 192,000
Warehouses various 21,622 $ 199,000
RMIS 1995 6,046 $ 87,000
- ----------
</TABLE>
(a) Includes two Sacramento locations.
8
<PAGE>
The following table indicates the principal diagnostic procedures available
at each of the imaging centers in which RadNet has a management and/or ownership
interest.
<TABLE>
<CAPTION>
Mammo- Ultra- Diagnostic Nuclear
Center MRI CT graphy sound Radiology Medicine
------ --- -- ------ ----- --------- --------
Wholly-Owned
- ------------
<S> <C> <C> <C> <C> <C> <C>
Tower Division:
Roxsan * * * * * *
120 East * * *
444 San Vicente * * *
1 West/Women's * *
Antelope Valley *
Lancaster * * * * *
Northridge * * * * * *
Orange * * * * *
Sacramento (DRI) * * * * *
San Francisco * *
Santa Clarita * * * * * *
Santa Rosa *
Stockton/Valley * * * * *
Tustin * * * * * *
Vacaville *
Ventura * * * * *
Joint Ventures
La Habra * *
Westchester * * * * *
</TABLE>
- ----------
*Indicates availability
RadNet's Management Services and Compensation
RadNet has entered into Management Agreements with respect to its
wholly-owned imaging centers with various physicians and physician groups (the
"Physician Group"). Pursuant to the typical Management Agreement, RadNet makes
available the imaging center facilities and all of the furniture, furnishings
and medical equipment at such facilities for use by the Physician Group and the
Physician Group is responsible for staffing the center with qualified medical
personnel. In addition, RadNet provides management services and administration
of the non-medical functions and services relating to the medical practice at
the center including among other functions, provision of clerical and
administrative personnel, bookkeeping and accounting services, billings and
collections, provision of medical and office supplies, secretarial, reception
and transcription services, maintenance of medical records, advertising,
marketing and promotional activities and the preparation and filing of all
forms, reports and returns required in connection with unemployment insurance,
workers' compensation insurance, disability, social security and similar laws.
As compensation for the services furnished under the Management Agreement,
RadNet is paid a Management Fee equal to an agreed percentage of the medical
practice billings, as and when collected, fluctuating from 70% to 85% of such
collections.
At the two joint venture imaging centers, RadNet has entered into a
Management Agreement to provide management, administrative and billing and
collection services for a management fee approximating 8% of the gross monthly
receipts received for services performed at the center. In addition, as a joint
venture partner, RadNet is entitled to 50% of joint venture income after
deduction of all expenses including amounts paid for medical services and
medical supervision.
At seven of the wholly-owned imaging centers (Antelope Valley, Lancaster,
Northridge, Orange, Santa Clarita, Stockton and Ventura), the medical services
including medical supervision are supplied by a partnership, Beverly Radiology
Medical Group ("BRMG"). The sole partners of BRMG are Drs. Howard Berger and
Michael Krane who are also principal stockholders of PHS. RadNet has a
Management and Services Agreement with BRMG for a ten-year term until June 2002,
terminable prior thereto at RadNet's election upon the occurrence of certain
events including a change in BRMG's
9
<PAGE>
ownership such that Drs. Berger and Krane are no longer owners in the aggregate
of at least 60% of the equity ownership of BRMG. As compensation for its
services furnished under the Management and Service Agreement, BRMG has agreed
to pay a Management Fee to RadNet equal to 79% of its medical practice billings
at the seven centers, as and when collected.
Equipment
The two most expensive types of diagnostic medical equipment found at the
imaging centers owned or managed by RadNet are the MRI and the CT systems. As
set forth in the chart under "RadNet Imaging Centers" above, fourteen centers
provide MRI services and fourteen centers provide CT services. MRI systems
generally cost between $1,500,000 and $2,000,000 and CT systems cost between
$500,000 and $1,000,000. A majority of the MRI systems and CT systems at
RadNet's imaging centers are manufactured by General Electric or Siemens. The
acquisition of these systems as well as the acquisition of the other relatively
expensive diagnostic medical equipment at the various imaging centers has been
effected through various financing arrangements directly with the manufacturer
involving the use of capital leases with purchase options at minimal prices at
the end of the lease term, the issuance of long term installment notes and the
use of operating leases with purchase options at substantial prices at the end
of the lease term. At October 31, 1995, capital lease obligations totaled
approximately $18,880,000 through October 31, 2001 including current
installments totaling approximately $4,700,000. Also at October 31, 1995,
installment notes payable totaled approximately $35,300,000 through October 31,
2001 including current installments of approximately $16,840,000. Commitments
under equipment operating leases at October 31, 1995 were approximately $800,000
through October 31, 2001 including current obligations of approximately
$428,000. To the extent additional imaging centers are opened or acquired, these
obligations will materially increase. See the above described chart as to the
other equipment available at each imaging center.
The MRI and CT systems and the other diagnostic medical equipment at the
imaging centers owned or managed by RadNet are subject to technological
obsolescence as medical imaging is a field in which there is constant
development of new techniques and technologies. In an attempt to minimize the
risk of obsolescence, RadNet and the joint ventures finance the acquisitions of
the majority of such equipment directly from the manufacturer rather than from a
third party finance company, which to date has facilitated the upgrading of such
systems and equipment to the latest "state of the art" developments on favorable
terms offered by the manufacturer.
Marketing
The patients who undergo diagnostic medical imaging procedures at the various
RadNet owned or managed imaging centers are generally referred by individual
independent physicians, by Independent Physician Associations ("IPAs")
consisting of groups of physicians, and by Health Maintenance Organizations
("HMOs"), Preferred Provider Organizations ("PPOs"), and similar organizations
which enroll subscribers on a contractual basis to whom they deliver healthcare
services. Such organizations attempt to control the cost of healthcare services
by directing their enrollees to participating physicians and institutions and
often through aggressive utilization review and limitations on access to
physician specialists, attempt to further limit the cost of medical service
delivery. Such organizations typically develop on a regional basis where an
appropriate enrollee population and mix of participating physicians and
institutions are available. Approximately 36% of the revenues generated for
diagnostic medical services performed at RadNet's imaging centers are
attributable to various IPAs, HMOs, PPOs, and similar organizations with the
balance primarily attributable to individual referring physicians.
RadNet currently employs nine full-time marketing and sales personnel who are
compensated on a salary plus commission basis and who periodically inform the
medical community including individual physicians and the administrators of
IPAs, HMOs, PPOs, and similar organizations throughout Southern California as to
the services provided at the RadNet owned or managed imaging centers. Patients
are obtained by direct referral or through contract. Some contracts, referred to
as "capitation contracts," provide for a fixed fee per organization member,
which is paid to the medical service provider. Under a "capitation" contract,
the provider agrees to provide specified services to the organization members
for a fixed, predetermined payment per member for a specified time period
(usually one year), regardless of how many times the member uses the service. No
assurances can be given that any of the current or future "capitation" contracts
will be profitable as there is a possibility that management could
10
<PAGE>
underestimate the number of times the services at its imaging centers will be
used by the contracting organization's members during the contract term.
Working Capital Requirements
RadNet's working capital needs are currently provided under a maximum
$7,000,000 line of credit due December 31, 1998 and made available by CoastFed
Business Credit Corporation ("CoastFed"). The credit line is collateralized by
substantially all of RadNet's accounts receivable except those of the Tower
Division. The line is restricted based on certain ratios being attained. At
October 31, 1995, outstanding borrowings under this line totaled approximately
$4,800,000. Borrowings under this line are repayable together with interest at
an annual rate equal to the greater of (a) the bank's prime rate plus 3%, or (b)
10%.
In December 1994 in connection with the operations of the Tower Division,
RadNet Sub obtained a maximum $4,000,000 revolving line of credit from DVI
Business Credit for working capital purposes. Under the revolving line of credit
agreement due December 1997, borrowings are permitted to the lesser of (a) up to
75% of eligible accounts receivable, (b) $4,000,000, or (c) cash collections for
the prior 120 days. The credit line is collateralized by approximately 80% of
the Tower Division's accounts receivable. At October 31, 1995, outstanding
borrowings under this line totaled approximately $1,300,000. Borrowings under
this line are repayable with interest equal to the lender's prime rate plus
3-1/2%. See "Business - RadNet - Equipment" herein as to RadNet's substantial
outstanding obligations in connection with the acquisition of diagnostic medical
equipment at the various imaging centers and Note 10 of Notes to the
Consolidated Financial Statements.
Competition
All of the imaging centers owned or managed by RadNet compete with a
substantial number of imaging centers in California, including centers located
at well-known hospitals in the area. Although no assurances can be given,
management believes RadNet's owned and managed imaging centers will be able to
successfully compete with such other centers because of the up-to-date imaging
equipment maintained at RadNet's centers, the quality of the medical personnel
affiliated with its centers and the fact that for widespread potential customer
groups, it has locations throughout the area.
Insurance
BRMG maintains a medical malpractice insurance policy in the amount of
$1,000,000 per occurrence and $3,000,000 in the aggregate covering each
physician obtained by it pursuant to its medical staffing obligations at the
various RadNet imaging centers. The policy provides ongoing coverage from any
claims made by patients seen by the physicians as well as coverage for all of
RadNet's non-medical personnel at each center against medical malpractice
claims. RadNet and PHS are also named insureds under the policy. All other
physicians who perform medical services at the various imaging centers are
required to maintain medical malpractice insurance coverage with similar limits.
Although management believes that such levels of insurance are adequate, there
can be no assurance in this regard. In addition, RadNet maintains $10,000,000 of
general liability insurance covering each center and its own principal offices
as well as all of its employees. BRMG and PHS are also named insureds under this
policy.
Employees
At December 31, 1995, RadNet had a total of 368 employees of whom nine served
in executive and managerial capacities, 151 supplied technical services at the
various imaging centers and the balance provided administrative, bookkeeping,
clerical and similar services.
None of RadNet's employees are subject to a collective bargaining agreement
nor has RadNet experienced any work stoppages. RadNet believes that its employee
relations are good.
Government Regulation
All of the Company's current operating revenues are attributable to its
operations in the health care services industry through RadNet. The health care
services industry in which the Company operates is subject to a wide range of
federal and state governmental regulatory requirements and prohibitions
11
<PAGE>
affecting all aspects of the Company's operations. Government regulation of the
health care services industry in general, and the occupational health care
industry in particular, may adversely affect the Company's business through,
among other things, potential reduction in payment for health care services.
Government regulation of the Company's health care service operations fall
into the following general areas: licensing, reimbursement, fraud/abuse,
corporate practice of medicine, and environmental.
Licensing - Health care facilities are subject to federal, state and local
regulation, and periodic inspection by licensing agencies to determine whether
the standards of medical care provided therein comply with licensing standards.
California law requires that professional health care services be provided only
by licensed physicians, a licensed facility, or a facility that qualifies for a
statutory exemption from licensure. The Company periodically verifies that the
physician providers at each of its centers maintain valid licenses to furnish
services, although the Company is to some extent dependent upon the physician
providers to which it furnishes management services to maintain such licensure.
Third Party Reimbursement - Providers of health care services, including
physicians, laboratories, and suppliers, receive payment for medical services
from their patients, from third party payors, or from a combination of both, but
third party reimbursement constitutes the great majority of revenues for most
health care providers. Third party payors include insurance companies,
government agencies, health maintenance organizations, preferred provider
organizations, and third party administrators for self-insured companies.
A significant portion of the Company's revenues is derived from the operation
or management of facilities that furnish diagnostic imaging services to patients
for which payment is made by third party payors such as the government-sponsored
health care programs, Medicare and Medicaid, the workers' compensation program,
and private insurers. The scope and amount of third party reimbursement has
become increasingly unpredictable during the past several years due to changes
in reimbursement formulas, utilization review mechanisms, and administrative
procedures effectuated by third party payors as part of their cost-containment
efforts, such as radiology fee schedules and a resource-based relative value
scale payment system for physician services.
Under most participation arrangements with governmental or third party
payors, including Medicare, Medicaid, Blue Cross/Blue Shield plans, and most
health maintenance organizations, health care providers are required to accept
as payment in full, amounts which may be less than established charges. Nearly
all governmental and third party payors require patients to pay a portion of the
approved payment amount in the form of deductibles and co-payments for services
received. Health care providers are often unable to collect deductibles and
co-payments at the time services are rendered, and in some cases not at all.
Claims submitted to third party payors for reimbursement may be denied,
returned, or reduced for many reasons, including ineligible beneficiary status,
non-covered services, lack of medical necessity, failure to provide sufficient
services to support the claim, secondary payor liability, failure to submit
required information and submission of incorrect billing information.
Coordination of benefits and subrogation rights also require special handling.
Corrections and resubmission of claims add to the cost of operations for health
care facilities.
Third party payors also usually engage in utilization review of claims to
verify that services are medically necessary and eligible for coverage. This
process further complicates and delays collections. Third party payors are, with
increasing frequency, replacing prospective (prior to services being rendered)
utilization review with retrospective (after services are delivered) review.
Such audits, which can relate to claims for service furnished several years
earlier, often result in efforts by the payor to recoup payments previously
approved.
Fraud and Abuse Issues - Federal and state law establish a large number of
prohibitions against billing and referral practices in the health care services
industry and impose criminal and civil penalties upon health care providers
found to have violated them.
Billing and Assignment - Under the Medicare and Medicaid programs, patients
usually assign their rights to payment to health care providers in exchange for
certain assurances from the health care providers, e.g., an agreement not to
bill for more than the Medicare approved amount. Health care providers are
generally restricted in their ability to reassign rights to Medicare or Medicaid
payment to
12
<PAGE>
third parties; an exception exists for billing and collection services under
specified conditions. Violation of the requirements for assignment or
reassignment can subject the health care provider to a range of criminal and
civil penalties, including fines and exclusion from the program.
Health care providers and management companies are also subject to criminal
and civil penalties under federal and state law prohibitions against submitting
false claims for payments. Generally, criminal penalties subjecting participants
to fines and imprisonment require that the entity act knowingly or willfully, or
with fraudulent intent. Civil statutes provide penalties for submitting claims
with "reckless disregard" of the truth or falsely submitting information. The
federal civil penalties statute provides for civil penalties against anyone who
presents or causes to be presented a false or improper claim under Medicare or
Medicaid, including billing agents. Liability is imposed on persons who "know or
should know" that a claim is "false," "fraudulent," or for services "not
provided as claimed."
In addition, health care providers and management companies are subject to
various other laws that provide for monetary sanctions for technical billing
violations and for failure to disclose known Medicare or Medicaid overpayments.
Health care providers and management companies are also subject to certain
federal and state credit collection agency laws and regulations and federal and
state anti-trust laws which, among other penalties, provide criminal penalties
for conspiring to fix prices. The Federal Fair Debt Collection Practices Act
(the "Federal Fair Debt Act") sets forth various provisions designed to
eliminate abusive, deceptive, and unfair debt collection practices by debt
collectors. The Federal Fair Debt Act also provides for a civil right of action
against any debt collector who fails to comply with the provisions thereof.
Various states, including California, also have promulgated laws and regulations
that govern credit collection practices. In general, these laws and regulations
prohibit certain fraudulent and oppressive credit collection practices and also
may impose license or registration requirements upon collection agencies. In
addition, state credit collection laws and regulations generally provide for
criminal fines, civil penalties, injunctions and jail terms for collection
agencies and collection agency personnel who fail to comply with such laws and
regulations. Although the Company does not provide past due or delinquent credit
collection services, the management services that it furnishes to its health
care providers may subject it to regulation as a "debt collector" under the
Federal Fair Debt Act and as a "collection agency" under certain state
collection agency laws and regulations.
Referral Arrangements- The Social Security Act (governing Medicare and
Medicaid) and many state laws impose civil and criminal penalties upon persons
who make or receive kickbacks, bribes, or rebates in connection with the
provision of health care services.
The federal anti-kickback rules prohibit individuals and entities from
knowingly and willfully soliciting, offering, receiving or paying, directly or
indirectly, any remuneration in return for (a) referring someone for a good,
facility, service or item, (b) purchasing, leasing, ordering or arranging for a
good, facility, service or item or (c) recommending that an individual purchase,
lease or order a good, facility, service or item reimbursable under the Medicare
or Medicaid programs. In addition to other penalties, violation of the
prohibitions can lead to exclusion from participation in the Medicare and
Medicaid programs, which would preclude a health care provider or the health
care clients of a management company from receiving reimbursement for services
furnished by the excluded entity. The Company believes that arrangements for the
management of medical practices such as it has established have in fact become
common in California, and have not generally been challenged with regard to
these issues. However, the Company cannot substantiate its belief. There can be
no assurance that the Company's present arrangements will not be challenged,
and, if challenged, that it will not be found to violate such prohibitions, thus
subjecting the Company to potential damages, injunction and/or civil and
criminal penalties.
California Business and Professions Code Section 650 sets forth a
comprehensive prohibition against the payment of compensation by or to a
physician or other health care professional in exchange for patient referrals.
An even more broadly worded prohibition on payments for referrals is found in
California Health and Safety Code Section 445, which applies by its terms to all
persons, not only physicians and other health care professionals, and prohibits
referrals for profit to "health-related facilities." The imaging centers
operated or managed by the Company are deemed "health-related facilities" under
the statute. However the Company does not believe that its present arrangements
violate the prohibition against referrals for profit contained in the statutes.
13
<PAGE>
All of the payment relationships under the management agreements entered into
by the Company are subject to review under the above statutes, as to whether any
portion of the payments is being made in exchange for the referral of patients.
Moreover, payment relationships with other persons and entities providing goods
or services to the Company, BRMG or the Company's other medical service
providers are also subject to review under the above statute as to whether any
of the payments for the goods or services are being made at least in part in
exchange for the referral of patients. Even if the Company were deemed to be
referring patients to the providers, the Company does not believe that any
portion of its management fee is being paid for such referrals, but rather
constitutes reasonable compensation for the services provided by the Company to
the providers pursuant to the management agreements. However, there can be no
assurances that the relationship between the Company and the health care
providers with which it contracts will not be characterized as violating the
statutes.
Future judicial, legislative or administrative action which interprets state
and federal "kickback" prohibitions could have a materially adverse effect on
the Company and its assets. Further, new legislation or regulations are proposed
periodically relating to referral patterns in the health care services industry
and there can be no assurance that the Company will be able to operate in
conformity with such laws and regulations or will be able to do so profitably.
As of January 1, 1995, both federal and California law prohibit referrals of
patients by physicians to a medical facility (including a diagnostic imaging
center) in which the physician or the physician's immediate family has a
financial interest. The federal law (the so-called "Stark Law") applies to
referrals of Medicare and Medicaid patients. The California version (the
so-called "Speier Law") extends the referral prohibition to all patients. These
laws are not applicable to RadNet's centers, as there is no referring physician
ownership or other financial interest in any of these facilities, except with
respect to Lancaster Imaging and Antelope Valley MRI as hereinafter described.
As of January 31, 1995, and in direct response to the Stark Law and Speier Law,
RadNet had purchased all of the referring physician ownership interests in
Lancaster Imaging and Antelope Valley MRI. The consideration used for these
completed "buy-out" transactions consisted of cash and secured promissory notes.
These secured promissory notes do constitute a "financial interest" under both
the Stark Law and the Speier Law. Management believes, based upon advice of
counsel, that there is an applicable exception in the Speier Law for secured
promissory notes. In other words, the ownership of the secured promissory notes
will not under the Speier Law prohibit the owning physicians from referring
their patients to these two RadNet facilities. Furthermore, there are exceptions
under both the Stark Law and the Speier Law for the referral of patients whose
services are paid for under a capitated arrangement. Accordingly, the only
remaining impact upon RadNet of the Stark Law and the Speier Law is that
Medicare and Medicaid patients who are not under a capitated arrangement cannot
legally be referred to RadNet's Lancaster Imaging and Antelope Valley MRI
facilities until the respective secured promissory notes are satisfied. The
Company believes that the bulk of RadNet's revenues from these two facilities
will not be adversely affected in a material manner, but no assurances can be
given that such will be the case. RadNet has reserved the right to prepay
without penalty all or part of the secured promissory notes, thus eliminating
any referral prohibition whatsoever. Although the Company believes that RadNet's
interpretation of the Stark Law and Speier Law is accurate with respect to the
applicable exceptions, there can be no assurances that such interpretations win
not be challenged by the appropriate authorities, and, if challenged, that
additional types of patient referrals will become prohibited.
Corporate Practice of Medicine - In California, a lay person or an entity
other than a professional corporation is not allowed to practice any of the
healing arts including by employing professional persons or by engaging
independent contractors, or have any ownership interest or profit participation
in or control over any healing arts professional practice. This doctrine is
commonly referred to as the prohibition on the "corporate practice" of medicine.
The Company believes that arrangements for the management of medical practices
have in fact become quite common in California, and have not generally been
challenged with regard to the corporate practice issue. However, because these
types of arrangements are not required to be reported, the Company cannot
substantiate its belief. There can be no assurance that RadNet's present
arrangements with BRMG or the physicians providing medical services and medical
supervision at RadNet's imaging centers will not be challenged, and, if
challenged, that they will not be found to violate the corporate practice
prohibition, thus subjecting the Company to potential damages, injunction and/or
civil and criminal penalties.
14
<PAGE>
The Company has not received a legal opinion from counsel with regard to the
effect of the corporate practice prohibition on its business as described
herein, and counsel has advised that such an opinion could not be given, because
of the lack of court cases relevant to the issue.
Environmental - The facilities operated or managed by the Company generate
hazardous and medical waste subject to federal and state requirements regarding
handling and disposal.
The Company believes that the facilities that it operates and manages are
currently in compliance in all material respects with applicable federal, state
and local statutes and ordinances regulating the handling and disposal of such
materials. The Company does not believe that it will be required to expend any
material amounts in order to remain in compliance with these laws and
regulations or that compliance will materially affect its capital expenditures,
earnings or competitive position.
The Company has not received a legal opinion from counsel with regard to the
effect of the prohibitions discussed above on its business as described herein,
and counsel has advised that such an opinion could not be given, because of the
fluid interpretation of the law relevant to the issue.
OTHER INVESTMENTS
Viromedics, Inc. ("VMI")
VMI is a privately owned development stage enterprise incorporated in
Delaware on February 14, 1989 to acquire and develop a procedure or method
utilizing an organic compound (the "Procedure") for the treatment of Acquired
Immune Deficiency Syndrome ("AIDS"). VMI acquired its interest in the Procedure
in May, 1989 and as assignee, on November 14, 1989, was issued U.S. Patent No.
4,880,836 (the "Patent") with respect thereto which Patent has not been
challenged to date. The Patent abstract described the patented Procedure as an
invention related to contacting the HIV virus (the virus which causes AIDS) or
the host cells, with a lower-alkyl-urea (the "compound") to prevent viral
penetration into the cells, thus preventing viral infection. VMI owned joint
patent rights to the Patent with The Albert Einstein College of Medicine
("AECOM") (located in New York City) pursuant to a licensing agreement with
AECOM effective May 29, 1990. On September 1, 1994, VMI renegotiated its
agreement with AECOM. Pursuant to the modified agreement, VMI assigned its
entire interest and rights in the Patent to AECOM in exchange for (a) the
release from all outstanding financial commitments due AECOM, and (b) a right to
20% of any monetary consideration received by AECOM for VMI's patent rights and
know-how, as defined.
At December 31, 1995, PHS was a minority (approximately 19%) stockholder with
a passive investment in VMI. PHS had no involvement in VMI's management and had
no ability to verify the present status of the research effort or VMI's ability
to meet its financial obligations. No assurances can be given that PHS will
realize any future return on its investment in VMI (although it has been repaid
all of the cash which it originally invested in VMI). See Note 13 of Notes to
the Consolidated Financial Statements herein.
Item 2. Properties
PHS maintains its principal executive offices in RadNet's approximately
11,500 square feet of leased office space at 1516 Cotner Avenue, Los Angeles,
California 90025. See Item 1 - "Business - RadNet" as to the imaging centers
owned, operated or managed by RadNet.
Item 3. Legal Proceedings
At November 1, 1993, the Company was a defendant in a putative class action
pending in the United States District Court for the District of New Jersey
entitled "In re Hibbard Brown & Company Securities Litigation." In March 1994,
the Court denied the plaintiffs' initial motion for class certification. The
plaintiffs subsequently amended the Consolidated Class Action Complaint and in
July 1994, filed a Second Amended and Consolidated Class Action Complaint (the
"Second Consolidated Complaint") in the matter. In the Second Consolidated
Complaint, the plaintiffs named as defendants, the Company, the Company's former
principal stockholder, Robert E. Brennan (the "Former Principal Stockholder")
and
15
<PAGE>
an entity allegedly controlled by the Former Principal Stockholder, F.N. Wolf &
Co., Inc. ("FNW"), the underwriter of the Company's December 1992 and June 1993
public offerings, FNW's parent company,Wolf Financial Group, Inc. ("WFG"),
Franklin N. Wolf, chairman and president of WFG and president of FNW, John E.
Dell, Hibbard Brown & Company, Inc. ("Hibbard"), a broker-dealer and its
president, Richard P. Brown and another publicly owned corporation,
Site-Based Media, Inc. ("Site").
In the Second Consolidated Complaint, the plaintiff identified certain
alleged "control" companies including among others, the Company, ITI, Digital
Products Corporation and Site and alleged that the defendants violated the
federal securities laws and the Racketeer Influenced Corrupt Organizations
("RICO") Act by initiating and/or joining in a conspiracy and course of conduct
designed to manipulate and artificially inflate the market prices of the stocks
of the various "control" companies in order to permit the defendants to sell
"large" amounts of the "control" companies' securities to the public at
manipulated prices and reap "huge" profits. The Second Consolidated Complaint
claims damages as well as punitive damages (including a trebling of damages
pursuant to the RICO statute), interest, attorneys' fees and costs, all of which
are unspecified in amount. In September 1994, the Court certified the matter as
a class action. Subsequent thereto, certain of the defendants, including the
Former Principal Stockholder, FNW, WFG and Hibbard filed for protection from
creditors pursuant to the federal bankruptcy laws.
Management contends that the Company was not a party to any conspiracy and
did not engage in any illegal course of conduct. Management believes that the
Second Consolidated Complaint is without merit with regard to the Company and
intends to vigorously contest same. However, as the proceeding is currently in
the early discovery stage, management is unable to evaluate the likelihood of an
unfavorable outcome or to estimate the amount or range of any potential loss.
In March 1993, the management of one of the Company's subsidiaries, Primedex
Corporation, whose operations were discontinued in July 1993), was made aware of
the prior issuance of a subpoena by a federal grand jury in Los Angeles seeking
to obtain certain records of the subsidiary in conjunction with a federal
investigation of an unrelated company. Subsequently, management was advised of
accusations of alleged health care fraud against the subsidiary which are being
investigated in the federal investigation in response to complaints made by
undisclosed third parties. On December 1, 1992, a number of the subsidiary's
locations (as well as at least 40 locations of other workers' compensation
healthcare providers) were searched by representatives of the Los Angeles
District Attorney's office in connection with an investigation of an advertising
service previously used by the subsidiary's affiliated entities and the other
providers concerning possible violations of California law in connection with
referral of patients. On June 22, 1994, additional searches of the premises of
the Company and its Primedex and RadNet subsidiaries were conducted by
representatives of the Los Angeles District Attorney's office pursuant to a
sealed affidavit which management has been unable to examine but which the
Company has been advised alleges violations of California penal laws concerning
securities and tax fraud, grand theft and criminal conspiracy. Management
believes that the Primedex subsidiary's operations have been and are in
compliance with applicable law, is unaware of any illegal activities of the
Company or its subsidiaries and is currently cooperating with the Los Angeles
District Attorney's office in connection with its investigation.
In connection with its cessation of operations at certain of its imaging
centers (Beverly Hills MRI - October 1993), (Beverly - October 1994) and
(Downtown Los Angeles - October 1994), lawsuits were filed against RadNet by the
lessors of the properties for past due rent, future rent and damage to the
premises plus costs. The lessor's lawsuit against RadNet relating to the
Downtown Los Angeles premises was settled in January 1996 with RadNet paying the
lessor a $425,000 settlement amount. As hereinafter described, PHS and RadNet
continue as cross defendants in a lawsuit brought by RadNet's former partners in
the Downtown Los Angeles imaging center. The monthly rent and lease expiration
dates for the other two facilities, with respect to which litigation brought by
the lessors of the properties is still pending, are as follows:
<TABLE>
<CAPTION>
Approximate Lease
Monthly Rent Expiration Date
<S> <C> <C>
Beverly Hills MRI $ 17,370 January 2000
Beverly $ 27,660 November 1999
</TABLE>
16
<PAGE>
Under California law, a landlord is required to use his best efforts to
mitigate damages. One method is by seeking to rent any vacated premises to
another tenant. Both the Beverly Hills MRI and the Beverly premises are
presently occupied by successor tenants, thus mitigating RadNet's damage
exposure. RadNet has asserted certain defenses in the lawsuit on the lease with
respect to the Beverly Hills MRI premises lease. This litigation is pending in
the California Superior Court; however, the Court has stayed any further
proceedings in this case until such time as the TME litigation hereinafter
described is concluded. The litigation relating to the Beverly premises lease is
presently in the discovery phase. RadNet has asserted certain defenses in this
lawsuit. The plaintiff/lessor has obtained an attachment of $1.1 million against
Howard Berger, the Company's chief financial officer and a director as well as
RadNet's chairman, the lessor asserting that Dr. Berger is also responsible for
this lease. RadNet intends to continue its vigorous defense of both of these
cases. No assurances can be given as to whether either of these lawsuits will be
settled or as to the amount of damages which RadNet will suffer under them.
In October 1995, the Company and RadNet were sued in a Cross-Complaint by a
number of individuals and entities led by Medical Imaging Center of Los Angeles
("MICLA"). The litigation relates to the Downtown Los Angeles facility, which
was closed in October 1994. In June 1993, RadNet acquired a 70% partnership
interest in Wilshire Imaging Group, L.P., a California limited partnership which
operated the Downtown Los Angeles facility. MICLA was one of the two limited
partners of Wilshire Imaging Group, L.P. In October 1994, due to changes in the
California Workers' Compensation system and the direct adverse impact of these
changes upon the Downtown Los Angeles facility's business, a decision was made
to close the facility. Since that time, a dispute has arisen among the parties
to Wilshire Imaging Group, L.P. concerning the payment of the liabilities of the
operation. DVI Financial Services, Inc., the major lender and equipment lessor
for this facility, brought a lawsuit against MICLA and others (not including
RadNet or the Company). MICLA and others named as defendants by DVI filed a
Cross- Complaint against the Company, RadNet, and Wilshire Imaging Group, L.P.
Outside the context of this litigation, RadNet and the Company has resolved all
differences with DVI and DVI and RadNet are proceeding with the various business
relationships with each other without any litigation between them. The
Cross-Complaint brought by MICLA against the Company and RadNet seeks "damages
in an amount which is presently unascertainable but which is in excess of
$1,000,000," punitive damages and treble damages. The lawsuit is in the
discovery phase. RadNet and the Company will continue to vigorously defend
against the claims raised in this lawsuit, and have filed a Counter-Claim
against MICLA and others seeking, among other remedies, the rescission of the
transaction in which Wilshire Imaging Group, L.P. was formed. No assurances or
predictions can be given at this time regarding the probable outcome of this
litigation.
In March 1994, RadNet and Drs. Berger and Krane (the two partners of BRMG),
as plaintiffs, filed a lawsuit in Federal District Court against TME, Inc. and
others. This Complaint alleges violations of federal securities law, fraud,
negligent misrepresentation, and a number of other related causes of action
arising out of the sale by TME of the Beverly Hills MRI facility to Drs. Berger
and Krane. On June 26, 1995, the Court granted RadNet's and the other
plaintiffs' motion for partial summary judgment against TME, thus holding that
TME in certain respects breached its contract for the sale of the Beverly Hills
MRI facility. The remaining issues in the case are scheduled for trial beginning
March 12, 1996. RadNet intends to continue its vigorous prosecution of its
claims in this matter. No assurances can be given at this time regarding the
outcome of this litigation.
The Company's subsidiaries are currently parties to other litigations, none
of which is deemed by management to be material in nature.
Item 4. Submission of Matters to a Vote of Security Holders
The Company did not submit any matters to a vote of security
holders during the fourth quarter of fiscal 1995.
17
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC.
PART II
Item 5. Market for the Registrant's Common
Stock and Related Stockholder Matters
PHS' Common Stock was traded on the NASDAQ National Market System
under the symbol "PMDX" since February 27, 1991 until April 13, 1995 when it was
delisted from trading on the NASDAQ System due to its failure to maintain the
required $1,000,000 of net tangible assets. Since such date, PHS Common Stock
has been traded in the over-the-counter market on the OTC Bulletin Board. The
following table indicates the high and low bid and asked prices for PHS Common
Stock for the periods indicated based upon information supplied by the National
Quotation Bureau, Inc.
<TABLE>
Bid Price(1) Asked Price(1)
<CAPTION>
Quarter Ended High Low High Low
<S> <C> <C> <C> <C>
January 31, 1994 3 1/4 2 1/4 3 3/8 2 1/2
April 30, 1994 2 7/8 2 3 2 1/8
July 31, 1994 2 7/8 13/16 3 15/16
October 31, 1994 1 3/32 17/32 1 3/16 9/16
January 31, 1995 15/16 13/32 1 7/16
February 1, 1995
through
April 13, 1995(2) 25/32 13/32 7/8 7/16
April 17, 1995
through
April 30, 1995 9/16 3/32 27/32 15/32
July 31, 1995 29/32 1/32 1 3/8 1/8
October 31, 1995 .16 1/32 .31 .08
</TABLE>
- ----------
(1) The above information reflects inter-dealer prices, without retail
mark-ups, mark-downs or commissions and may not necessarily represent actual
transactions.
(2) The Common Stock was delisted from the NASDAQ National Market System
after April 13, 1995.
The closing bid and asked prices for PHS Common Stock on the OTC Bulletin
Board on December 29, 1995 were $.20 and $.25 respectively. As of December 29,
1995, the number of holders of record of PHS Common Stock was 2,814. However, a
substantial number of PHS' outstanding shares of Common Stock were owned of
record on said date by "Cede & Co.," the nominee for Depository Trust Company,
the clearing agency for most broker-dealers. Management believes that these
shares are beneficially owned by customers of these broker-dealers and that the
number of beneficial owners of PHS Common Stock is substantially greater than
2,814.
18
<PAGE>
Item 6. Selected Consolidated Financial Data
[In thousands, except per share data]
<TABLE>
Y e a r s e n d e d
O c t o b e r 3 1,
<CAPTION>
1 9 9 5 1 9 9 4 [B] 1 9 9 3 1 9 9 2 [A] 1 9 9 1 [A]
------- ------- ------- ------- -------
<S> <C> <C> <C> <C> <C>
Operating Data:
Gross Revenues ............................. $ 88,884 $ 69,942 $ 70,122 $ 36,599 $ --
Operating Expenses ......................... $ 98,124 $ 50,289 $ 50,414 $ 20,951 $ 202
[Loss] from Investee Transactions .......... $ -- $ (26) $ (648) $ (215) $ (685)
Income [Loss] from Continuing
Operations [Exclusive of
Non-Recurring Items] - Net of
Taxes ** ................................. $ (57,616) $ (20,476) $ (16,004) $ 1,009 $ (675)
Income [Loss] from Discontinued
Operations ............................... $ (3,813) $ (3,371) $ (39,646) $ 3,715 $ --
Net [Loss] Income Before Extraordinary
Item ..................................... $ (62,370) $ (20,912) $ (47,787) $ 18,457 $ (675)
Extraordinary Item - Gain ..................... $ 941 $ -- $ -- $ -- $ --
[Loss] Income Per Common Share
From Continuing Operations
Before Extraordinary Items ............... $ (1.54) $ (.44) $ (.21) $ .51 $ (.03)
[Loss] Income Per Common Share from
Discontinued Operations .................. $ (.09) $ (.08) $ (1.04) $ .13 $ --
Loss [Gain] Before Extraordinary Item ......... $ (1.63) $ (.52) $ (1.25) $ .64 $ (.03)
Net [Loss] Income Per Common Share ......... $ (1.61) $ (.52) $ (1.25) $ .64 $ (.03)
Cash Dividends Per Common Share ............ $ -- $ -- $ -- $ -- $ --
Balance Sheet Data:
Cash and Cash Equivalents .................. $ 3,929 $ 5,649 $ 24,557 $ 27,323 $ 7,420
Total Assets * ............................. $ 66,760 $ 153,551 $ 188,151 $ 209,710 $ 11,579
Total Long-Term Liabilities ................ $ 54,088 $ 67,666 $ 58,668 $ 63,363 $ --
Total Liabilities .......................... $ 82,002 $ 104,522 $ 107,698 $ 110,628 $ 24
Working Capital [Deficit] .................. $ (4,337) $ 528 $ 16,970 $ 34,130 $ 7,411
Stockholders' Equity [Deficit] ............. $ (15,242) $ 49,029 $ 80,452 $ 99,082 $ 11,554
</TABLE>
19
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
SUMMARY CONSOLIDATED FINANCIAL INFORMATION
- ------------------------------------------------------------------------------
[In thousands, except per share and ratio data]
[A] The operating data for October 31, 1992, gives retroactive effect to
discontinued operations of the Primedex Subsidiary.
[B] The operating data for October 31, 1994, gives effect to the spin off of
the Care Advantage, Inc.
subsidiary as of October 31, 1994.
* At October 31, 1995, 1994 and 1993, includes $15,383, $58,725 and $50,820
of goodwill, respectively.
** Reconciliation of Income from Continuing Operations - Net of Taxes
O c t o b e r 3 1,
1 9 9 5 1 9 9 4
--------------- -------------
Net [Loss] ......................... $(61,429) $(20,912)
Loss from
Discontinued Operations ............ 3,813 3,371
[Loss] from Continuing Operations
Inclusive of Non-Recurring Items] -
Net of Taxes (57,616) (17,541)
Less: Nonoperating Gain from Investee
Stock Transactions [See Note 2]
$ -- $ 2,935
Net of Approximate Taxes ..... -- -- -- 2,935
------- -------- -------- ---------
[Loss] from Continuing Operations
[Exclusive of Non-Recurring Items]
- - Net of Taxes .............. $(57,616) $(20,476)
======= ========
20
<PAGE>
ITEM 7.
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- ---------------------------------------------------------------------------
Background
Primedex Health Systems, Inc. ["PHS"] [formerly CCC Franchising Corp.] was
incorporated on October 21, 1985.
On November 1, 1990, the Company acquired a 51% interest in Viromedics, Inc.
["VMI"] for $700,000. On February 18, 1992, Future Medical Products ["FMP"], the
parent corporation of VMI, exercised its right to repurchase one-half of the VMI
stock from PHS at a price of $700,000. The Company owns approximately 19% of
VMI's outstanding capital stock at October 31, 1995, which is accounted for
using the cost method at $-0-.
During fiscal 1992, the Company purchased approximately 90% of the common stock
of ImmunoTherapeutics, Inc. ["ITI"]. For 1995 and 1994, the Company owned
approximately 19% of ITI and accounted for this investment using the cost
method, which was $-0- at October 31, 1995 and 1994.
In November of 1995, this investment was sold for $143,750.
As of January 31, 1992, the Company's wholly-owned subsidiary, CCC Franchising
Acquisition Corp. I, entered into an asset purchase agreement with Primedex
Corporation ["Primedex"] for approximately $46,250,000. On July 29, 1993, the
Company announced its plans to restructure its Primedex subsidiary and to wind
down its involvement in the California worker's compensation industry.
Accordingly, the operating results of this subsidiary have been reclassified as
a discontinued operation and the appropriate prior period amounts have been
restated. Effective August 1, 1995, substantially all of the assets of Primedex
were sold to an unrelated party for approximately $9,448,000. The sale resulted
in a loss of approximately $3,800,000.
As of April 30, 1992, the Company's wholly-owned subsidiary, CCC Franchising
Acquisition Corp. II, entered into a purchase agreement with Radnet Management,
Inc. and certain related companies [Radnet] for approximately $66,000,000. The
Statements of Operations and Cash Flows for the years ended October 31, 1995 and
1994 reflect the operations and cash transactions with Radnet.
On December 23, 1993, the Company acquired Advantage Health Systems, Inc.
["AHS"], a newly organized corporation formed to provide medical and surgical
utilization reviews for major providers of health insurance, for $6,000,000 in
cash. On August 26, 1994, the Company announced a plan to spin-off its
subsidiary, Care Advantage, Inc. [CareAd] which owns AHS. The operations of this
subsidiary have been classified as a discontinued line of business [See Note
21].
Effective November 1, 1995, the Company acquired most of the assets of Future
Diagnostics, Inc. by purchasing 100% of its outstanding stock for approximately
$3.2 million consisting of cash, notes and assumed assets and liabilities.
Founded in 1989, FDI is a leading Radiology management service organization
providing network development and management along with diagnostic imaging cost
containment and utilization review services.
Discussion of Operations for the Year Ended October 31, 1995 vs. October 31,
1994
The following discussion relates to the continuing activities of Primedex Health
Systems, Inc.
Results of Operations
The discussion of the results of continuing operations includes Radnet for the
years ended October 31, 1995 and 1994.
21
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- -------------------------------------------------------------------------------
Discussion of Operations for the Years Ended October 31, 1995 vs. October 31,
1994
Results of Operations [Continued]
On July 29, 1993, the Company announced its plans to restructure its Primedex
subsidiary and to wind down its involvement in the California worker's
compensation industry. Accordingly, the operating results of this subsidiary
have been classified as a discontinued operation and appropriate prior period
amounts have been restated. On August 26, 1994, the Company announced a plan to
spin-off the CareAd subsidiary. The operating loss of this subsidiary has been
classified as a discontinued segment for fiscal 1994.
For the years ended October 31, 1995 and 1994, the Company had operating losses
from continuing operations of $52,779,293 and $15,849,869, respectively. Radnet
realized an operating loss of approximately $50,600,000. For the year ended
October 31, 1995 and 1994, Radnet had net revenues of $45,344,878 and
$34,439,271, respectively. The increase was due to the acquisition of the Tower
Imaging Group in October of 1994.
For the years ended October 31, 1995 and 1994, operating expenses totaled
approximately $98,124,172 and $50,289,140, respectively. Radnet's October 31,
1995 operating expenses totaled approximately $95,883,525. Radnet's October 31,
1995 operating expense increase was primarily attributable to the implementation
of FASB 121 and the resulting recognition of an impairment loss of approximately
$47,744,453 for the write-down of related goodwill and property, plant and
equipment [See Note 6]. Other October 31, 1995 Radnet operating expenses include
approximately $20,195,000 for wages and compensation. $8,300,000 of depreciation
and amortization, and $19,645,000 of other general and administrative expenses.
Wages and compensation of approximately $1,100,000 were incurred by PHS.
Effective August 1, 1995, the Primedex subsidiary sold substantially all of its
assets for approximately $9,448,000. The Primedex subsidiary operating results
are reflected as discontinued operations. The sale generated a loss of
approximately $3,800,000. Approximately $700,000 remains on the Company's books
for estimated final costs associated with this operation [See Note 20].
For the years ended October 31, 1995 and 1994, interest income was approximately
$296,000 and $244,000, respectively. For the years ended October 31, 1995 and
1994, interest expense was approximately $6,200,000 and $6,100,000,
respectively. Interest expense of Radnet was primarily attributable to equipment
financing, acquisition notes payable and lines of credit charges. In December of
1995, interest rates on the Company's two revolving lines of credit were each
reduced by 1%.
For the years ended October 31, 1995 and 1994, the Company had net losses from
continuing operations of $57,615,472 and $17,541,283, respectively. The October
31, 1995 loss is comprised of $47,744,453 for the FASB 121 impairment loss and
$9,871,019 of other operating losses.
The Company continues to aggressively pursue new contracts from managed care
organizations, to seek strategic alliances and/or acquisitions, to maximize the
marketing effectiveness of its network of centers, and to improve its cost
structure and delivery systems.
22
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- ------------------------------------------------------------------------------
Discussion of Operations for the Years Ended October 31, 1995 vs. October 31,
1994
Liquidity and Capital Resources
Cash decreased for the years ended October 31, 1995 and 1994 by $1,720,398 and
$18,907,810, respectively. The October 31, 1994 decrease in cash was primarily
attributable to approximately $6,800,000 in advances to Care Advantage,
$6,500,000 in payments on stockholder's notes payable, and $10,000,000 in
acquisition costs. Cash utilized for investing activities for the years ended
October 31, 1995 and 1994 was $3,625,510 and $9,724,449, respectively. Cash
utilized for financing activities for the years ended October 31, 1995 and 1994
was $9,978,884 and $13,080,425, respectively. For the year ended October 31,
1995, approximately $8,300,000 was made in debt and lease payments,
approximately $1,800,000 was advanced from short-term borrowings, approximately
$500,000 was paid on stockholder's notes payable, and approximately $2,900,000
was advanced to CareAd as part of the separation agreement. The Company
capitalized this advance to CareAd and $6,800,000 advanced in fiscal 1994 as
part of the separation agreement [See Note 21].
At October 31, 1995, the Company had working capital deficit of $4,337,436 as
compared to working capital of $527,301 at October 31, 1994, a decrease of
$4,864,637. A primary reason for the decrease was the reclassification of
approximately $5,200,000 of notes payable as current debt in which the Company
has suspended making payments and is in negotiation with an outside lender.
The Radnet operation utilized approximately $650,000 in cash from operations for
the year ended October 31, 1995. Radnet utilized cash of approximately
$1,076,000 in the acquisition of four centers including the remaining joint
venture interests in Lancaster Imaging Group, Antelope Valley MRI and Santa
Clarita Imaging Center, and the purchase of Women's Diagnostic Imaging Center,
which was subsequently merged into the Tower division.
Radnet's future payments for debt and equipment under capital leases for the
next five years, assuming lines of credit are paid and not renewed, will be
approximately $21,500,000, $7,950,000, $7,700,000, $6,550,000 and $3,400,000.
The October 31, 1995 lines of credit balances are approximately $6,000,000. In
addition, $5,200,000 of notes payable was reclassified as current while the
Company is in negotiation with the outside lender. Interest expense for the next
five years, included in the above payments, will be approximately $4,000,000,
$2,100,000, $1,500,000, $950,000 and $600,000, respectively. In addition, Radnet
has noncancellable operating leases for use of its facilities and certain
medical equipment which will average approximately $3,300,000 in annual payments
over the next five years.
In fiscal 1995, the Company successfully renegotiated the majority of its
equipment under capital lease liabilities and some notes payable with a major
outside lender deferring all payments until February 1996, standardizing
favorable interest rates, eliminating large balloon payments, and extending
remaining lease terms to seven to ten years from October 31, 1995.
The Company has committed to expenditures of at lease $1,250,000 over the next
year to develop a centralized scheduling, transcription, billing and collection
system. The major supplier of equipment to the Company has agreed to provide
financing for substantially all of the project.
The Company acquired Future Diagnostics, Inc. for approximately $3,200,000 in
cash, notes payable and assumed liabilities on November 1, 1995. Cash to be
utilized in the purchase include $105,000 upon the closing and $839,842 due on
January 2, 1996. Both of these amounts were paid in early 1996. In addition,
four quarterly payments of $50,000 will commence on February 29, 1996, followed
by eight quarterly payments of $75,000, four quarterly payments of $100,000 and
a final lump- sum of $200,000 on December 31, 1999.
The Company estimates interest payments on its bond debentures to be
approximately $2,584,100 in fiscal 1996. The quarterly payments of approximately
$646,025 are paid on January 1, April 1, July 1 and October 1 of each year.
23
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- ------------------------------------------------------------------------------
Discussion of Operations for the Years Ended October 31, 1995 vs. October 31,
1994
Liquidity and Capital Resources [Continued]
Radnet's working capital needs are currently provided under two lines of credit.
Under one agreement, due December 31, 1998, the Company may borrow the lesser of
75% to 80% of eligible accounts receivable, $7,000,000 or the prior 120-days'
cash collections. Borrowings under this line are repayable together with
interest at an annual rate equal to the greater of (a) the bank's prime rate
plus 3%, or (b) 10%. The lender holds a first lien on substantially all of
Radnet's assets to secure repayment under the line of credit. At October 31,
1995, approximately $4,800,000 was outstanding under this line. A second line of
credit was obtained in December of 1994 subsequent to the acquisition of the
Tower Imaging Group. Under this agreement, due December 1997, the Company may
borrow the lesser of 75% of the eligible accounts receivable, $4,000,000 or the
prior 120-days' cash collections. The credit line is collateralized by
approximately 80% of the Tower division's [Radnet Sub, Inc.] accounts
receivable. At October 31, 1995, approximately $1,200,000 was outstanding under
this line.
A third line of credit has been obtained for the Company's Future Diagnostics
subsidiary in early 1996. The division will be able to borrow up to 80% of the
net collectible value of eligible commercial insurance and worker's compensation
receivables, $1,000,000 or the prior 60-day's cash collections. As of January
1996, $-0- has been borrowed under this line.
In connection with ceasing operations at certain of the Radnet imaging centers,
lawsuits have been filed against the Radnet subsidiary by lessors of the
properties for past due rent, future rent and damages to the properties plus
other costs. The aggregate monthly rentals through the terms of each of the
related leases approximates $2,500,000. The Radnet subsidiary has and will
assert defenses to each of these lawsuits; however, no assurances can be given
that any of these suits will settle or as to the amount of damages, if any,
Radnet will incur. Radnet has accrued approximately $1,250,000 for past due rent
and legal costs.
In fiscal 1995, Radnet did successfully settle its outstanding liability with
one building lessor for $425,000. In addition, a discrimination lawsuit
discussed in last year's 10-K was settled for $210,000. The Company is also
party to a number of other lawsuits discussed in Note 13.
New Authoritative Pronouncements
The Financial Accounting Standards Board ["FASB"] issued Statement of Financial
Accounting Standards ["SFAS"] No. 123, "Accounting for Stock-Based
Compensation," in October 1995. SFAS No. 123 uses a fair value based method of
accounting for stock options and similar equity instruments as contrasted to the
intrinsic valued based method of accounting prescribed by Accounting Principles
Board [APB] Opinion No. 25, "Accounting for Stock Issued to Employees." The
Company has not decided if it will adopt SFAS No. 123 or continue to apply APB
Opinion No. 25 for financial reporting purposes. SFAS No. 123 will have to be
adopted for financial statement note disclosure purposes in any event. The
accounting requirements of SFAS No. 123, if adopted by the Company, will be
effective for transactions entered into in fiscal years that begin after
December 15, 1995; the disclosure requirements of SFAS No. 123 are effective for
financial statements for fiscal years beginning after December 15, 1995.
On December 30, 1994, the American Institute of Certified Public Accountants
issued Statement of Position [SOP] 94-6, "Disclosure of Certain Significant
Risks and Uncertainties," the provisions of which are effective for financial
statements issued for fiscal years ending after December 15, 1995. In general,
SOP 94-6 requires disclosures about the nature of a company's operations and the
use of estimates in the preparation of financial statements. The Company does
not anticipate a significant expansion of its financial statement note
disclosure as a result of SOP 94-6.
Inflation
To date, inflation has not had a material effect on the Company's operations.
24
<PAGE>
ITEM 7.
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- ------------------------------------------------------------------------------
Discussion of Operations for the Year Ended October 31, 1994 vs. October 31,
1993
Results of Operations
The discussion of the results of continuing operations includes Radnet for the
year ended October 31, 1994. For the year ended October 31, 1993,
ImmunoTherapeutics, Inc. ["ITI"] and the Radnet operations are included.
On July 29, 1993, the Company announced its plans to restructure its Primedex
subsidiary and to wind down its involvement in the California worker's
compensation industry. Accordingly, the operating results of this subsidiary
have been classified as a discontinued line of business and appropriate prior
period amounts have been restated.
On August 26, 1994, the Company announced a plan to spin-off the CareAd
subsidiary. Accordingly, the operating loss of this subsidiary has been
classified as a discontinued line of business.
For the years ended October 31, 1994 and 1993, the Company had operating losses
from continuing operations of $15,849,869 and $15,205,880, respectively. Radnet
realized an operating loss of approximately $12,300,000, which included a
restructuring provision of approximately $3,700,000 [See Note 9 to the Financial
Statements]. For the year ended October 31, 1994, Radnet realized net revenues
of approximately $34,400,000. For the year ended October 31, 1994, operating
expenses totaled approximately $50,300,000 of which approximately $46,700,000
were incurred by the Radnet operation, and approximately $3,600,000 were
incurred by PHS, the parent corporation. Operating expenses for Radnet consisted
of wages and compensation of approximately $16,850,000, depreciation and
amortization of approximately $6,700,000, other general and administrative
expenses of approximately $19,450,000 and restructuring charges of approximately
$3,700,000. Wages and compensation of approximately $1,200,000 were incurred by
PHS.
During fiscal 1994 and 1993, Radnet continued to be impacted by the effects of
managed care and heavy competition for radiological procedures. Accordingly, in
the second quarter Radnet provided $1,500,000 and an additional $3,200,000
during the remainder of fiscal 1994 in contractual adjustments relating to the
accounts receivable. A portion of the accounts receivable contractual
adjustments were related to reductions in the worker's compensation fee schedule
effective January 1, 1994. Radnet is continuing to improve its cost structures
and delivery systems. It is also aggressively pursuing new contracts and has
established an operational restructuring plan to minimize the ongoing effects of
continuing market dynamics and to strengthen its competitive position for the
future. This plan anticipates the consolidation or closure of certain centers,
adjustments to certain professional and technical contractual arrangements,
reductions in fixed expenditures and changes to the equipment complement or
service offerings of certain centers.
On January 17, 1994, a major earthquake affected the Northridge and Santa
Clarita imaging centers and caused disruptions in business throughout the area.
Although all of the imaging centers including Northridge and Santa Clarita
continued to operate, the disruption adversely affected Radnet's business in
January and during the first half of February 1994. There has been no continuing
adverse effect on Radnet's business due to the earthquake since such time.
The Primedex subsidiary reduced its accrued closing costs by approximately
$7,900,000 [through settlements or payments] for the year ended October 31,
1994. The Primedex subsidiary operating results are reflected as discontinued
operations.
25
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- -------------------------------------------------------------------------------
Discussion of Operations for the Years Ended October 31, 1994 vs. October 31,
1993
Results of Operations [Continued]
For the years ended October 31, 1994 and 1993, interest income was approximately
$244,000 and $1,100,000, respectively. For the years ended October 31, 1994 and
1993, interest expense was approximately $6,100,000 and $5,300,000,
respectively. Interest of approximately $1,000,000 was reclassified from
interest expense of the continuing operations and was allocated to accrued
estimated closing costs for the year ended October 31, 1994. In January of 1993,
the Company utilized primarily all of the net proceeds of its December 1992
public offering to repay a $30,000,000 note payable. Interest expense of Radnet
was primarily attributable to equipment financing.
For the years ended October 31, 1994 and 1993, the Company had net losses from
continuing operations of $17,541,282 and $8,140,599, respectively.
Liquidity and Capital Resources
The following discussion on liquidity and capital resources includes Primedex
and Radnet as of October 31, 1994.
Cash decreased for the years ended October 31, 1994 and 1993 by $18,907,810 and
$2,765,848, respectively. Cash provided from operations for the year ended
October 31, 1994 was $3,897,114 and cash used by operations for the year ended
October 31, 1993 was $3,517,457. Cash utilized for investing activities for the
years ended October 31, 1994 and 1993 was $9,724,499 and $9,760,339,
respectively.
Cash utilized for financing activities for the year ended October 31, 1994 was
$13,080,425. Cash generated from financing activities for the year ended October
31, 1993 was $10,511,948. During 1994, the Company made principal payments to
three individuals totaling $6,500,000 on stockholder notes payable. For the year
ended October 31, 1994, approximately $6,000,000 was made in debt and lease
payments and approximately $6,100,000 was advanced from short-term borrowings.
At October 31, 1994, the Company had working capital of $527,201 as compared to
a working capital of $16,970,015 at October 31, 1993, a decrease of $16,442,814.
This decrease is primarily attributable to the losses sustained by the Radnet
subsidiary.
The Radnet operation generated approximately $600,000 in cash from operations
for the year ended October 31, 1994.
The Antelope Valley MRI Center option was exercised during 1993, and Radnet's
partner filed a lawsuit against Radnet seeking to obtain approximately $2.8
million as the purchase price for its interest, instead of Radnet's position
that the fixed formula results in a price of $1.35 million. Although it was
Radnet's position that this option was legally invalid, and Radnet was therefore
not obligated to purchase its partner's interest in the Antelope Valley
facility, Radnet and its partner continued discussions for the buyout of this
partner's interest. In January 1995, the Company settled this lawsuit and agreed
to a "buy-out" price of $1,700,000 of which Radnet paid $400,000 upon closing.
Of the $1,300,000 balance, an aggregate $300,000 is payable in four quarterly
installments in calendar 1995 with interest at the rate of 8% per annum until
January 1, 1996 and then payable with 16 quarterly installments of principal
through October 1, 1999.
The Radnet subsidiary is also a party to a number of other lawsuits, none of
which are deemed to be material in nature.
26
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- -------------------------------------------------------------------------------
Discussion of Operations for the Years Ended October 31, 1994 vs. October 31,
1993
Liquidity and Capital Resources [Continued]
The CareAd operation utilized approximately $3,000,000 for operations,
$6,100,000 for investing activities, and generated approximately $12,743,000
from financing activities.
Management's plans for the Radnet subsidiary include aggressively pursuing new
contracts and having established an operational restructuring plan to minimize
the ongoing effects of continuing market dynamics and to strengthen its
competitive position for the future. This plan anticipates the consolidation or
closure of certain centers, adjustments to certain professional and technical
contractual arrangements, reductions in fixed expenditures and changes to the
equipment complement or service offerings of certain centers. It is anticipated
that the Company will be able to fund its programs internally or through the
Radnet subsidiary.
New Authoritative Pronouncements
The Financial Accounting Standards Board ["FASB"] has issued Statement of
Financial Accounting Standards ["SFAS"] No. 109, "Accounting for Income Taxes,"
and SFAS 107, "Disclosure about Fair Value of Financial Instruments." The
Company adopted SFAS 109 effective November 1, 1993. Adoption of the new
statement did not have a material impact on the Company's financial position or
results of operations. SFAS 107 has been adopted on October 31, 1993. The FASB
has also issued SFAS 115, "Accounting for Certain Investments in Debt and Equity
Securities," which the Company will adopt on November 1, 1994. In October of
1994, the FASB issued SFAS No. 119, "Disclosure above Derivative Financial
Instruments and Fair Value of Financial Instruments." While SFAS No. 119
primarily creates new disclosure requirements for derivative financial
instruments which the Company does not trade in at this time, the technical
disclosure amendments to SFAS No. 107 created by SFAS No. 119 will be
implemented on November 1, 1995. The adoption of SFAS No. 107 and 119 will not
have a material impact on the Company's financial position or results of
operations.
Inflation
To date, inflation has not had a material effect on the Company's operations.
27
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- -----------------------------------------------------------------------------
INDEX
- -----------------------------------------------------------------------------
Page to Page
Independent Auditor's Report............................... F-1.........
Consolidated Balance Sheets................................ F-2......... F-3
Consolidated Statements of Operations...................... F-4......... F-5
Consolidated Statements of Stockholders' Equity [Deficit].. F-6.........
Consolidated Statements of Cash Flows...................... F-7......... F-8
Notes to Consolidated Financial Statements................. F-9......... F-24
Independent Auditor's Report on Supplemental Schedule...... S-1.........
Schedule II - Valuation and Qualifying Accounts............ S-2......... S-4
. . . . . . . . . . . . . . .
<PAGE>
INDEPENDENT AUDITOR'S REPORT
To the Stockholders and Board of Directors of
Primedex Health Systems, Inc.
New York, New York
We have audited the accompanying consolidated balance sheets
of Primedex Health Systems, Inc. and its affiliates as of October 31, 1995 and
1994, and the related consolidated statements of operations, stockholders'
equity [deficit], and cash flows for each of the three fiscal years in the
period ended October 31, 1995. These consolidated financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted
auditing standards. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the consolidated
financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall consolidated financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the consolidated financial
position of Primedex Health Systems, Inc. and its affiliates as of October 31,
1995 and 1994, and the consolidated results of their operations and their cash
flows for each of the three fiscal years in the period ended October 31, 1995,
in conformity with generally accepted accounting principles.
The accompanying consolidated financial statements have been
prepared assuming that the Company will continue as a going concern. As
discussed in Note 24 to the consolidated financial statements, the Company has
suffered recurring losses from operations, has negative working capital, and has
defaulted on certain loans which raises substantial doubt about its ability to
continue as a going concern. Management's plans in regard to these matters are
also described in Note 24. The consolidated financial statements do not include
any adjustments that might result from the outcome of these uncertainties.
As discussed in the accompanying notes to the financial
statements, for the year ended October 31, 1995, the Company adopted two new
accounting standards promulgated by the Financial Accounting Standards Board,
changing its methods of accounting for impairments of long-lived assets and
goodwill related to those assets, and certain investments in debt and equity
securities.
MORTENSON AND ASSOCIATES, P. C.
Certified Public Accountants.
Cranford, New Jersey
January 12, 1996, except
as to Notes 10 and 23, for
which the date is February 7, 1996
F-1
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- ---------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEETS
- ---------------------------------------------------------------------------
<TABLE>
<CAPTION>
October 31,
1 9 9 5 1 9 9 4
<S> <C> <C>
Assets:
Current Assets:
Cash and Cash Equivalents .................................................................. $ 3,928,832 $ 5,649,230
Marketable Security ........................................................................ 1,956,707 --
Accounts Receivable - Net .................................................................. 16,011,324 14,305,238
Accounts Receivable - Net - Discontinued Operation ......................................... -- 12,171,228
Accrued Revenue ............................................................................ 304,871 946,170
Due from Related Party ..................................................................... 87,500 --
Other ...................................................................................... 264,452 529,663
------------ ------------
Total Current Assets ....................................................................... 22,553,686 33,601,529
------------ ------------
Property, Plant and Equipment - Net ........................................................... 17,270,032 26,753,778
------------ ------------
Property, Plant and Equipment - Net - Discontinued Operation .................................. -- 778,887
------------ ------------
Other Assets:
Accounts Receivable - Net .................................................................. 5,653,654 6,130,816
Accounts Receivable - Net - Discontinued Operation ......................................... -- 19,630,067
Due from Related Parties ................................................................... 2,697,437 2,490,703
Goodwill - Net ............................................................................. 15,382,944 58,725,489
Other ...................................................................................... 3,201,951 5,439,424
------------ ------------
Total Other Assets ......................................................................... 26,935,986 92,416,499
------------ ------------
Total Assets ............................................................................... $ 66,759,704 $153,550,693
============ ============
</TABLE>
See Notes to Consolidated Financial Statements.
F-2
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- ------------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEETS
- ------------------------------------------------------------------------------
<TABLE>
<CAPTION>
October 31,
-----------
1 9 9 5 1 9 9 4
------- -------
<S> <C> <C>
Liabilities and Stockholders' Equity [Deficit]:
Current Liabilities:
Accounts Payable $ 1,918,337 $ 3,093,237
Notes Payable - Stockholders' -- 2,500,000
Accrued Expenses - Current 4,182,150 4,710,939
Notes and Leases Payable - Current 17,565,435 14,871,927
Accrued Estimated Closing Costs - Current 487,447 5,700,000
Accrued Restructuring Costs 1,250,000 1,225,000
Other 1,487,755 973,225
---------------- ----------------
Total Current Liabilities 26,891,124 33,074,328
---------------- ----------------
Long-Term Liabilities:
Subordinated Debentures Payable 25,841,000 25,875,000
Notes and Leases Payable 26,741,081 34,661,928
Accrued Estimated Closing Costs 243,723 6,411,948
Accrued Expenses 1,261,899 717,669
---------------- ----------------
Total Long-Term Liabilities 54,087,703 67,666,545
---------------- ----------------
Commitments and Contingencies -- --
---------------- ----------------
Minority Interest 1,023,343 3,780,879
---------------- ----------------
Stockholders' Equity [Deficit]:
Common Stock - $.01 Par Value, 100,000,000 Shares Authorized; 40,230,760 and
40,026,510 Shares Issued and Outstanding at October 31, 1995 and 1994,
Respectively 402,307 400,265
Paid-in Capital 99,399,165 102,243,835
Retained Earnings [Deficit] (115,043,938) (53,615,159)
---------------- ----------------
Total Stockholders' Equity [Deficit] (15,242,466) 49,028,941
---------------- ----------------
Total Liabilities and Stockholders' Equity [Deficit] $ 66,759,704 $ 153,550,693
================ ================
</TABLE>
See Notes to Consolidated Financial Statements.
F-3
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- ------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
- ------------------------------------------------------------------------------
<TABLE>
Y e a r s e n d e d
O c t o b e r 3 1,
<CAPTION>
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
Revenue:
<S> <C> <C> <C>
Revenue $ 88,884,136 $ 69,942,395 $ 70,121,861
Less: Allowances 43,539,257 35,503,124 34,914,147
----------------- ----------------- ----------------
Net Revenue 45,344,879 34,439,271 35,207,714
----------------- ----------------- ----------------
Operating Expenses:
Operating Expenses 40,599,493 37,277,623 34,018,644
Depreciation and Amortization 8,625,336 7,012,087 6,892,207
Provision for Bad Debts 1,154,890 2,669,914 4,896,337
Restructuring Costs -- 3,329,516 4,606,406
Impairment Loss of Long-Lived Assets 47,744,453 -- --
----------------- ----------------- ----------------
Total Operating Expenses 98,124,172 50,289,140 50,413,594
----------------- ----------------- ----------------
Loss from Operations (52,779,293) (15,849,869) (15,205,880)
----------------- ----------------- ----------------
Other [Expenses] and Revenue:
Interest Expense (6,184,302) (6,057,769) (5,312,142)
Interest Income 295,609 243,733 1,080,248
Other Income 409,741 487,226 337,451
Non-Operating Income -- 2,934,504 7,862,931
----------------- ----------------- ----------------
Total Other [Expenses] Revenue (5,478,952) (2,392,306) 3,968,488
----------------- ----------------- ----------------
Loss Before Income Taxes, Minority
Interest in [Income] Loss of Subsidiaries,
Equity in Loss of Investees, and
Extraordinary Item (58,258,245) (18,242,175) (11,237,392)
Provision for Income Taxes -- -- 4,180,000
Minority Interest in [Income] Loss of Subsidiaries (298,104) 726,740 (435,639)
Equity in Loss of Investees -- (25,847) (647,568)
----------------- ----------------- ----------------
Loss from Continuing Operations - Forward $ (58,556,349) $ (17,541,282) $ (8,140,599)
</TABLE>
See Notes to Consolidated Financial Statements.
F-4
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- --------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
- -------------------------------------------------------------------------
<TABLE>
Y e a r s e n d e d
O c t o b e r 3 1,
<CAPTION>
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
<S> <C> <C> <C>
Loss from Continuing Operations - Forwarded ...... $(58,556,349) $(17,541,282) $ (8,140,599)
------------ -------------
Discontinued Operation:
Loss from Operations of Discontinued Business
Segments [Net of Income Taxes
of $-0-, $-0- and $2,500,173 for the Years Ended
October 31, 1995, 1994 and 1993, Respectively] . (3,813,314) (3,370,771) (141,019)
Estimated Loss on Discontinued Business Segment
Including Provision for Operating Loss of
$46,525,095 During Phase-Out Period [Net of
Income Tax [Benefit] of Approximately
($7,020,000)] .................................. -- -- (39,505,095)
------------ -------------
Total Discontinued Operation ..................... (3,813,314) (3,370,771) (39,646,114)
------------ -------------
Loss Before Extraordinary Item ................... (62,369,663) (20,912,053) (47,786,713)
Extraordinary Item - Gain from Extinguishment
of Debt .......................................... 940,884 -- --
------------ -------------
Net Loss ......................................... $(61,428,779) $(20,912,053) $ (47,786,713)
========== ===============
Loss Per Share:
Loss from Continuing Operations .................. $ (1.54) $ (.44) $ (.21)
Loss from Operations of Discontinued
Business Segment [Net of Income Tax] ........... (.09) (.08) (.01)
Estimated [Loss] on Discontinued Business
Segment ........................................ -- -- (1.03)
------------- ------------ -------------
Loss Before Extraordinary Item ................... (1.63) (.52) (1.25)
Extraordinary Item ............................... .02 -- --
----- ------------ -------------
Net Loss Per Share ............................... $ (1.61) $ (.52) $ (1.25)
===== ============ ==============
Weighted Average Common Shares
Outstanding .................................... 40,031,461 40,026,510 38,260,311
========== ========== ==============
</TABLE>
See Notes to Consolidated Financial Statements.
F-5
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- -----------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [DEFICIT]
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Total
Common Stock Retained Stckhlds
Number of Par Value Paid-in Earnings Equity
Shares Amount Capital [Deficit] [Deficit]
<S> <C> <C> <C> <C> <C>
Balance - October 31, 1992 ....................................32,362,500 $ 323,625 $ 81,045,564 $ 17,712,835 $ 99,082,024
Issuance of Common Stock and Warrants
Net of Offering Expenses of $3,872,130 ................... 7,589,010 75,890 30,417,635 -- 30,493,525
Issuance of Common Stock - Vista Acquisition ............... 75,000 750 299,250 -- 300,000
Decrease in Equity from Sale of ImmunoTherapeutics Stock ... -- -- (1,636,794) -- (1,636,794)
Net [Loss] for the Year Ended October 31, 1993 ............. -- -- -- (47,786,713) (47,786,713)
---------- ----------- ----------- ----------- -----------
Balance - October 31, 1993 ....................................40,026,510 400,265 110,125,655 (30,073,878) 80,452,042
Decrease in Equity from the Sale of ImmunoTherapeutics Stock -- -- (2,078,385) -- (2,078,385)
Forgiveness of Debt - Shareholder .......................... -- -- 1,000,000 -- 1,000,000
Capitalization of Advances - Care Advantage ................ -- -- (6,803,435) -- (6,803,435)
Stock Dividend - Care Advantage ............................ -- -- -- (2,629,228) (2,629,228)
Net [Loss] for the Year Ended October 31, 1994 ............. -- -- -- (20,912,053) (20,912,053)
Balance - October 31, 1994 ....................................40,026,510 400,265 102,243,835 (53,615,159) 49,028,941
---------- ----------- ----------- ----------- -----------
Capitalization of Additional Advances - CareAd ............. -- -- (2,896,628) -- (2,896,628)
Issuance of Common Stock ................................... 200,000 2,000 18,000 -- 20,000
Conversion of Subordinated Debentures to Common Stock ...... 4,250 42 33,958 -- 34,000
Net [Loss] for the Year Ended October 31, 1995 ............. -- -- -- (61,428,779) (61,428,779)
---------- ----------- ----------- ----------- -----------
Balance - October 31, 1995 ....................................40,230,760 $ 402,307 $ 99,399,165 $(115,043,938) $ (15,242,466)
</TABLE>
See Notes to Consolidated Financial Statements.
F-6
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- -------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Y e a r s e n d e d
O c t o b e r 3 1,
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
<S> <C> <C> <C>
Operating Activities:
Net [Loss] $ (61,428,779) $ (20,912,053) $ (47,786,713)
----------------- ----------------- ------------
Adjustments to Reconcile Net [Loss] to Net Cash
Provided [Used] by Continuing Operations:
Discontinued Operations 3,813,314 -- 19,767,704
Equity in Loss of Investees -- 25,843 647,568
Depreciation and Amortization 8,625,336 7,012,087 6,892,207
Deferred Income Taxes -- -- (11,200,000)
Minority Interest in Income of Subsidiaries 298,104 (726,740) 435,639
Provision for Bad Debts 1,154,890 2,669,914 4,896,337
Loss [Gain] on Sale of Assets 279,646 (96,094) 388,438
Provision for Closed and Restructured
Imaging Center -- 4,218,434 4,606,406
Imputed Interest Income - Related Party (206,734) (570,297) (373,698)
Equipment Write-Down -- -- 1,700,000
Write-off of Goodwill -- 281,082 6,991,213
Write Down of Long-Lived Assets 47,744,453 -- --
Extraordinary Gain from Extinguishment of Debt (940,884)
Compensation from Sale of Stock 18,000 -- --
Changes in Assets and Liabilities:
[Increase] Decrease in:
Other Current Assets 57,934 1,018,133 762,942
Accounts Receivable (2,272,574) 14,491,537 6,031,602
Prepaid Insurance -- -- (860,675)
Accrued Revenue 641,299 344,730 1,091,503
Other Assets 348,104 (448,256) 357,017
Increase [Decrease] in:
Due to/from Related Parties (337,121) 179,473 2,890,881
Accounts Payable and Accrued Expenses (610,490) (921,017) (444,914)
Other -- -- (791,400)
Other Current Liabilities (146,187) 481,960 480,486
----------------- ----------------- ----------------
Total Adjustments 58,467,090 27,960,789 44,269,256
----------------- ----------------- ----------------
Cash Provided [Used] by Continuing Operations (2,961,689) 7,048,736 (3,517,457)
Cash Provided [Used] by Discontinued Operations 14,845,685 (3,151,622) --
----------------- ----------------- ----------------
Net Cash - Operating Activities - Forward $ 11,883,996 $ 3,897,114 $ (3,517,457)
</TABLE>
See Notes to Consolidated Financial Statements.
F-7
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- -------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Y e a r s e n d e d
O c t o b e r 3 1,
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
<S> <C> <C> <C>
Net Cash - Operating Activities - Forwarded $ 11,883,996 $ 3,897,114 $ (3,517,457)
----------------- ----------------- ----------------
Investing Activities:
Acquisitions of Imaging Centers - Net of Cash
Acquired (1,076,096) -- (3,821,712)
Purchase of Property, Plant and Equipment (592,707) (376,890) (846,309)
Sale of ImmunoTherapeutics -- (262,507) (5,379,111)
Distributions to Joint Venture -- -- (786,000)
Acquisition Costs -- (10,385,000) --
Proceeds - Sale of Equipment -- 1,271,916 1,072,793
Proceeds from Joint Venture -- 27,982
Purchase of Marketable Securities (2,478,707) -- --
Sale of Marketable Securities 522,000 -- --
----------------- ----------------- ----------------
Net Cash - Investing Activities (3,625,510) (9,724,499) (9,760,339)
----------------- ----------------- ----------------
Financing Activities:
Principal Payments on Capital Leases and Notes (8,268,319) (5,917,756) (8,116,623)
Proceeds from Short-Term Borrowings
on Notes Payable 1,784,067 6,139,762 2,058,324
Principal Payments on Notes Payable -- -- (30,000,000)
Proceeds - Sale of Stock and Exchange of Warrants -- -- 30,682,747
Net Proceeds from Issuance of Convertible
Debentures -- -- 23,387,500
Advances - Care Advantage (2,896,632) (6,802,431) --
Payments on Stockholder Notes Payable (500,000) (6,500,000) (17,500,000)
Joint Venture Distribution (100,000) -- --
Proceeds of Stockholder Note Payable -- -- 10,000,000
Proceeds from Sale of Stock 2,000 -- --
----------------- ----------------- ----------------
Net Cash Financing Activities (9,978,884) (13,080,425) 10,511,948
------------------ ----------------- ----------------
Net [Decrease] in Cash and Cash Equivalents (1,720,398) (18,907,810) (2,765,848)
Cash and Cash Equivalents - Beginning of Years 5,649,230 24,557,040 27,322,888
----------------- ----------------- ----------------
Cash and Cash Equivalents - End of Years $ 3,928,832 $ 5,649,230 $ 24,557,040
================= ================= ================
Supplemental Disclosures of Cash Flow Information:
Cash paid during the years for:
Interest $ 5,957,981 $ 6,973,133 $ 4,788,625
Income Taxes $ -- $ 86,393 $ 826,640
</TABLE>
Supplemental Schedule of Non-Cash Investing and Financing Activities:
The Company entered into capital leases of approximately $1,156,000 during
the year ended October 31, 1995.
During fiscal 1995, subordinated debentures totaling $34,000 were converted
into 4,250 shares of the Company's common stock.
During fiscal 1994, the Company acquired medical equipment of approximately
$3,400,000 for a loan as part of an acquisition.
During fiscal 1995, a $2,500,000 note payable to a stockholder was settled
for a cash payment of $500,000 [See Note 19].
See Notes to Consolidated Financial Statements.
F-8
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- -------------------------------------------------------------------------------
[1] Summary of Significant Accounting Policies
[A] Organization, Business and Basis of Presentation - Primedex Health Systems,
Inc. ["PHS" or the "Company"] was incorporated on October 21, 1985 and is
principally engaged in the diagnostic imaging business in the state of
California.
The accompanying combined and consolidated financial statements include the
accounts of PHS, Primedex Corporation ["Primedex"] and Radnet Management, Inc.
["Radnet"]. Radnet is combined and consolidated with Beverly Radiology Medical
Group ["BRMG"], Radnet Sub, Inc. ["Radsub"] and three joint ventures: La Habra
Imaging Group, Westchester Imaging Group and Wilshire Imaging Group
["Wilshire"] [collectively the "Company"]. Wilshire was closed in late 1994.
All intercompany transactions and balances have been eliminated.
Medical services and supervision at Radnet's wholly-owned imaging centers are
provided through BRMG, which is owned by two shareholders of PHS and through
other various independent physicians and physician groups. Radnet provides
non-medical, technical and administrative services including operation of
medical equipment, facility maintenance, marketing, advertising, billing and
collection, and other financial and administrative services. As compensation for
its management and other services at the various centers, Radnet receives a
management fee. In connection with the imaging centers in which it is a joint
venture partner, Radnet also shares in joint venture income.
For many of the patients serviced at the Company's centers, the cost of the
service is borne by third party payors. The difference between the Company's
list price for such services and the amount the Company agrees to accept from
such third party payors results in contractual adjustments.
During fiscal 1992, the Company purchased approximately 90% of the common stock
of ImmunoTherapeutics, Inc. ["ITI"]. For fiscal 1993, the investment was
accounted for using the equity method due to the decline in percentage of
ownership during the year to 42%. For 1995 and 1994, the Company owned
approximately 19% of ITI and accounted for this investment using the cost
method, which was $-0- at October 31, 1995 and 1994. In November of 1995, this
investment was sold for $143,750.
The Company owns 19% of the outstanding capital stock of Viromedics, Inc.
["VMI"] at October 31, 1995. This investment is accounted for using the cost
method, which at October 31, 1995 is $-0-.
[B] Cash and Cash Equivalents - Cash equivalents are comprised of certain highly
liquid investments with a maturity of three months or less when purchased. The
carrying amount of cash and cash equivalents approximates their fair value.
[C] Property, Plant and Equipment and Depreciation and Amortization - Property,
plant and equipment are stated at cost, less accumulated depreciation and
amortization, and includes equipment held under capital lease agreements.
Depreciation is computed by the straight-line method and is based on the
estimated useful lives of the various assets ranging from three to forty years.
Leasehold improvements are amortized over the shorter of the life of the lease
or their estimated useful life, using the straight-line method.
F-9
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #2
- ------------------------------------------------------------------------------
[1] Summary of Significant Accounting Policies [Continued]
[D] Accounts Receivable and Allowances - Accounts receivable are stated at gross
amounts billed less allowances. A significant portion of the Company's accounts
receivable involve third party payors, primarily insurance companies. The
Company's collection cycle on accounts receivable from continuing operations
extends up to thirty-six months. However, most worker's compensation and
personal injury cases have a longer collection cycle. The current portion of
accounts receivable are the amounts which are reasonably expected to be
collected within a year, based upon historical collection data.
Accounts receivable as of October 31, 1995 are shown net of allowances for
doubtful accounts of $19,986,242 of which $15,633,140 has been deducted in
current assets and $4,353,102 has been deducted in other assets.
Accounts receivable from continuing operations as of October 31, 1994 are shown
net of allowances for doubtful accounts of $16,837,753 of which $11,786,427 has
been deducted in current assets and $5,051,326 has been deducted in other
assets.
[E] Goodwill - Goodwill is recognized in business combinations accounted for
under the purchase method of accounting and represents the excess of the
purchase price over the fair value of identifiable net assets acquired. Goodwill
is amortized on a straight-line basis over twenty years which is the period the
Company expects to receive benefits.
Management of the Company evaluates the periods of goodwill amortization to
determine whether later events and circumstances warrant revised estimates of
useful lives. Management also evaluates whether the carrying value of goodwill
has become impaired. The evaluation is done by analyzing the projected
discounted net cash flows from operations.
Effective for fiscal 1995, the Company has adopted Statement of Financial
Accounting Standards ["SFAS"] No. 121, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to be Disposed Of" [See Note 6].
[F] Accrued Expenses - Accrued expenses consist primarily of outside
professional services, interest and payroll.
[G] Revenue Recognition and Accrued Revenues - Revenue is recognized at the time
services are provided. Accrued revenues consist primarily of services performed
prior to period end, which were not billed. Billing is usually completed within
the following month.
[H] Reclassification - Certain items from the prior years' financial statements
have been reclassified to conform to the current year's presentation.
[I] Concentrations of Credit Risk - Financial instruments which potentially
subject the Company to concentrations of credit risk are cash and cash
equivalents and accounts receivable arising from its normal business activities.
The Company routinely assesses the financial strength of its customers and third
party payors and, based upon factors surrounding their credit risk, establishes
an allowance for uncollectible accounts, and as a consequence, believes that its
accounts receivable credit risk exposure beyond such allowances is limited. The
Company places its cash and cash equivalents with high credit quality financial
institutions. The amount on deposit in any one institution that exceeds
federally insured limits is subject to credit risk. The Company had
approximately $209,180 and $4,821,137 as of October 31, 1995 and 1994,
respectively, with financial institutions subject to a credit risk beyond the
insured amount. The Company has not experienced any losses in such accounts.
F-10
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #3
- -------------------------------------------------------------------------------
[2] Business Combinations and Acquisitions
In December of 1991, PHS acquired approximately 90% of ITI for $445,000
consisting of cash and a note payable. The acquisition was accounted for as a
purchase.
During fiscal 1993, the Company sold approximately 2,000,000 shares of ITI stock
for net proceeds of approximately $7,900,000, resulting in a non-operating gain
of approximately $7,900,000 for the year. In November of 1993, the Company paid
$162,762 to ITI in full payment of the balance from the 1991 purchase of common
stock. In December of 1993, a registration statement of ITI was declared
effective registering an aggregate of 1,304,224 shares of ITI common stock owned
by the Company. In consideration for the filing of the registration statement,
the Company granted to the Chief Executive Officer of ITI an option expiring on
December 31, 2003 to purchase 575,000 shares of ITI stock owned by the Company
at a purchase price of $3.00 per share and granted this officer a proxy during
the option term to vote such shares. During fiscal 1994, the Company sold
1,304,224 shares of ImmunoTherapeutics stock for net proceeds of approximately
$2,934,504, resulting in a non-operating gain of $2,934,504.
At October 31, 1993, ITI was carried on the equity method at $1,842,723. As of
October 31, 1994 and 1995, the Company owned 1,150,001 shares representing
approximately a 19% interest which was carried on the cost method, which equaled
$-0-. Subsequent to the year end, the shares were sold for $143,750.
The Company acquired certain of the assets and liabilities of Primedex in
January of 1992 for $46,250,000 consisting of cash and stock. Primedex was a
southern California based medical management company that provided services to
medical corporations, which in turn provided medical/legal evaluation services
and medical services to worker's compensation claimants. In connection with the
purchase, the Company incurred $30,000,000 in debt financing which was repaid in
fiscal 1993. The acquisition was accounted for under the purchase method and
resulted in goodwill of approximately $7,300,000, which was written off in July
1993 in connection with the discontinuance of Primedex's operations [See Note
20].
In April of 1992, the Company acquired certain assets and liabilities of Radnet
for approximately $66,000,000 consisting of stock, cash and a note payable. The
Company also loaned $6,000,000 to the sellers [See Note 7]. The acquisition was
accounted for under the purchase method resulting in goodwill of approximately
$51,500,000.
Radnet has acquired various percentage interests in imaging centers in
transactions accounted for as purchases generally involving a mixture of cash,
notes and common stock:
During fiscal 1993, 1994 and 1995, Radnet acquired Santa Clarita Imaging Center
Limited Partnership for $102,000 cash.
In April of 1993, the remaining 50% interest in the Northridge Imaging Group
Joint Venture was acquired for $2,500,000 consisting of cash and a note.
Approximately $575,000 of goodwill resulted from this transaction. The Company
renegotiated the $1,500,000 note due in fiscal 1995.
In May of 1993, the assets of Vista X-Ray Laboratory Limited were acquired for
$400,000 consisting of cash and common stock, resulting in goodwill of
approximately $430,000.
In July 1993, Radnet acquired the assets of two diagnostic imaging centers
located in Sacramento, California from Diagnostic Radiological Imaging Medical
Group ["DRI"] for approximately $4,049,000 consisting of cash, a note and
assumed liabilities resulting in $2,200,000 of goodwill.
F-11
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #4
- -------------------------------------------------------------------------------
[2] Business Combinations and Acquisitions [Continued]
In June of 1993, Radnet acquired a 70% interest in Wilshire Imaging Group, L.P.
for $357,000 cash resulting in goodwill of $303,000. In late 1994, due to
changes in the California worker's compensation system and its direct adverse
impact on this clinic's business the operation was closed. As part of the fiscal
1994 restructuring, expenses of approximately $1,300,000 were incurred in the
write-off and write-down of certain intangibles and property and equipment.
In October of 1993, Radnet acquired the assets of Valley Imaging Center Limited
Partnership for $865,000 in cash and notes resulting in approximately $300,000
of goodwill and in September of 1994, Radnet acquired Stockton Diagnostic
Radiology & Ultrasound for $410,000 in cash, a note and assumed capital leases
resulting in goodwill of approximately $210,000. The two practices were
subsequently merged to consolidate resources and enhance efficiency.
In March of 1994, Radnet acquired the remaining 50% interest in the Ventura
Coast Imaging Center Joint Venture for $1,677,000 consisting of cash and a note
resulting in goodwill of approximately $242,000.
In April of 1994, Radnet acquired all of the assets of Orange Imaging Medical
Center for $150,000 consisting of cash and a note resulting in goodwill of
$214,000.
In October of 1994, the assets of Tower Imaging Group ["Tower"] were acquired
for $13,265,000 consisting of cash, a note and an assumed liability resulting in
goodwill of approximately $9,850,000.
In November of 1994, Radnet acquired the remaining 50% interest in the Lancaster
Radiology Medical Group Joint Venture for $872,194 consisting of cash and a note
and resulting in goodwill of approximately $215,000.
In January of 1995, the remaining 50% interest of the Antelope Valley MRI, L.P.
was acquired for $1,700,000 consisting of cash and a note resulting in goodwill
of approximately $2,800,000.
In January of 1995, Radnet acquired the assets of Women's Diagnostic Medical
Group for cash of $200,000. The transaction resulted in goodwill of $425,000.
In November of 1995, subsequent to the year end, all of the outstanding capital
stock of Future Diagnostics, Inc. ["FDI"] was acquired for $2,345,000 consisting
of cash and notes resulting in goodwill of approximately $3,200,000. FDI is in
the business of the marketing and utilization review of radiological services.
[3] Marketable Securities
The Company adopted Statement of Financial Accounting Standards ["SFAS"] No.
115, "Accounting for Certain Investments in Debt and Equity Securities," at
November 1, 1994. SFAS No. 115 addresses the accounting and reporting for
investments in equity securities that have readily determinable fair values and
for all investments in debt securities. Those investments are to be classified
into the following three categories: held-to-maturity debt securities, trading
securities, and available-for-sale securities. In accordance with SFAS No. 115,
prior years' financial statements are not to be restated to reflect the change
in adopting the new accounting method. There was no cumulative effect as a
result of adopting SFAS No. 115 at November 1, 1994.
F-12
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #5
- --------------------------------------------------------------------------------
[3] Marketable Securities [Continued]
Management determines the appropriate classification of its investments in debt
securities at the time of purchase and reevaluates such determination at each
balance sheet date. Debt securities for which the Company does not have the
intent or ability to hold to maturity are classified as available for sale.
Securities available for sale are carried at cost which approximates fair value.
At October 31, 1995, the Company had no investments that qualified as trading or
held to maturity. The Company had no marketable securities at October 31, 1994.
As of October 31, 1995, the Company's investments consist of $5,414,195 of U.S.
Government Treasury Bills of which $3,457,488 is classified as cash and cash
equivalents and $1,956,707 is classified as a marketable security which matures
March 28, 1996.
Sales of available for sale securities held during the year amounted to
$522,000. Gains on sale of securities are insignificant. The Company uses
specific identification in calculating realized gains and losses.
[4] Fair Value of Financial Instruments
Estimated fair value of the Company's financial instruments [all of which are
held for nontrading purposes] are as follows:
<TABLE>
<CAPTION>
1 9 9 5 1 9 9 4
------- -------
Carrying Fair Carrying Fair
Amount Value Amount Value
<S> <C> <C> <C> <C>
Cash and Marketable Securities $ 5,885,539 $ 5,885,539 $ 5,649,230 $ 5,649,230
Debt Maturing within One Year 14,310,341 14,310,341 12,628,705 12,628,705
Long-Term Debt 15,150,661 12,300,000 20,721,001 17,200,000
Subordinates Debentures 25,841,000 23,419,927 25,875,000 23,238,782
</TABLE>
The carrying amount approximates fair value of cash and marketable securities.
The fair value of long-term debt is based on current rates at which the Company
could borrow funds with similar remaining maturities.
[5] Property, Plant and Equipment and Depreciation and Amortization
Property, plant and equipment and accumulated depreciation and amortization as
of October 31, 1995 and 1994 are as follows:
<TABLE>
<CAPTION>
1 9 9 5 1 9 9 4
------- -------
<S> <C> <C>
Land $ 1,763,773 $ 1,844,387
Building 2,373,983 2,398,757
Medical Equipment 6,673,323 8,789,664
Office Equipment and Furniture and Fixtures 1,316,548 1,821,710
Leasehold Improvements 2,332,263 1,949,713
Property Held Under Capital Leases 12,503,868 17,199,976
--------------- ---------------
Totals 26,963,758 34,004,207
Less: Accumulated Depreciation and Amortization (9,693,726) (7,250,429)
--------------- ---------------
Property, Plant and Equipment - Net $ 17,270,032 $ 26,753,778
----------------------------------- =============== ===============
</TABLE>
Depreciation expense for fiscal 1995, 1994 and 1993 was approximately
$4,200,000, $4,200,000 and $3,800,000, respectively.
For property held under capital leases, depreciation expense for the year ended
October 31, 1995 was approximately $2,011,000 and the accumulated depreciation
was approximately $7,333,000.
Certain assets were written down during fiscal 1995 [See Note 6].
F-13
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #6
- ------------------------------------------------------------------------------
[6] Intangible Assets
A breakdown of intangible assets is as follows:
<TABLE>
<CAPTION>
Accumulated
Cost Amortization Net
<S> <C> <C> <C>
October 31, 1994:
Goodwill $ 65,673,308 $ 6,947,819 $ 58,725,489
---------------- --------------- ================
Covenants Not-to-Compete $ 2,420,618 $ 326,113 $ 2,094,505
---------------- --------------- ================
October 31, 1995:
Goodwill $ 16,343,942 $ 960,998 $ 15,382,944
---------------- --------------- ================
</TABLE>
Covenants not-to-compete are included in the caption "Other Assets" on the
balance sheet.
Amortization expense of approximately $4,400,000, $2,800,000 and $3,100,000 was
recognized for the years ended October 31, 1995, 1994 and 1993, respectively.
Effective for fiscal 1995, the Company adopted SFAS No. 121, "Accounting for
Impairment of Long- Lived Assets and for Long-Lived Assets to be Disposed Of."
The Company recorded an impairment loss of $47,744,453 from writing down
goodwill, property and equipment and covenants not-to-compete. Facts and
circumstances leading to the impairment loss consist principally of the
application of the measurement techniques of SFAS No. 121 to the cash flows of
the Company's individual imaging centers as it relates to projections of cash
flows which are insufficient to justify the carrying values of certain
long-lived assets. Fair value was determined for individual centers primarily
through estimating the fair value of their property, plant and equipment
consisting primarily of medical equipment. The impairment loss recorded is the
difference between these estimated fair values and the carrying values of all
centers, including goodwill allocated to individual centers in connection with
the Radnet acquisition, based on pro-rata estimated fair values at the date of
the acquisition. Significant assumptions for the cash flow forecast are a ten
year period and insignificant changes to revenues and costs over the projected
period.
[7] Due from Related Parties
The amount due from related parties originally consisted of a $6,000,000 loan to
the sellers of Radnet [See Note 2]. This loan was originally discounted at a 7%
interest rate which resulted in interest income for fiscal 1993 of $374,000. In
October 1993, the installment note due February 1994 was extended until August
1994. In August of 1994, the Company and the two former owners agreed to offset
approximately $3,000,000 of the loan against $2,500,000 due to them by PHS and
the waiver of rights to payments aggregating $500,000. The remaining $3,000,000
receivables were further extended in October of 1994 from February 1, 1995 to
February 1, 1997 in consideration for the two individuals agreeing to utilize
their personal assets as collateral for future loans. A discount of
approximately $500,000 was recorded in fiscal 1994 on the transaction which was
reflected as a reduction to interest income.
The notes are secured by stock of PHS, which was issued in connection with the
Radnet acquisition.
During fiscal 1995, the Company loaned $87,500 to an officer/stockholder at no
interest. Management expects the amount to be collected within a year.
F-14
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #7
- -------------------------------------------------------------------------------
[8] Income Taxes
The composition of the provision [benefit] for income tax expense consists of:
<TABLE>
Y e a r s e n d e d
O c t o b e r 3 1,
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
<CAPTION>
<S> <C> <C> <C>
Federal:
Current $ -- $ -- $ --
Deferred -- -- (3,800,000)
State:
Current -- -- --
Deferred -- -- (380,000)
---------------- ----------------- -----------------
Totals $ -- $ -- $ (4,180,000)
------ ================ ================= =================
</TABLE>
The following is a reconciliation of taxes at the U.S. statutory tax rate to
the taxes actually provided:
<TABLE>
Y e a r s e n d e d
O c t o b e r 3 1,
<CAPTION>
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
<S> <C> <C> <C>
Federal Statutory Expense [Benefit] .... $ -- $ -- $(3,800,000)
Operating Losses with no Current Benefit -- -- --
State Tax .............................. -- -- (380,000)
---------------- ------------------ -----------
Actual Tax Expense ................... $ -- $ $(4,180,000)
- ---------------------------------------- ================ ================== ===========
</TABLE>
The Company has net operating loss carryforwards of approximately $57,500,000
with the following expiration dates:
Years ended
2007 $ 1,500,000
2008 21,900,000
2009 16,900,000
2010 17,200,000
----------------
$ 57,500,000
As a result of these carryforwards and temporary differences relating
principally to depreciation, loss accruals and the write off of intangible
assets, the Company has a deferred tax asset of approximately $26,000,000, which
has been offset by a valuation account of $26,000,000, resulting in a net
deferred tax asset of $-0-. Future tax benefits related to these losses have not
been recognized because their realization is not assured. In addition, the
Company had a significant stock ownership change in fiscal 1995, therefore
limiting loss carryovers based upon present Internal Revenue Regulations.
[9] Provision for Closed and Restructured Imaging Centers
During fiscal 1993, a provision of approximately $4,600,000 was recorded for the
closing of a center which included the write-off and write-down of leasehold
improvements and medical equipment, the accrual of lease cancellation costs, and
the write-off of a note receivable from a medical director of the center.
F-15
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #8
- -------------------------------------------------------------------------------
[9] Provision for Closed and Restructured Imaging Centers [Continued]
During fiscal 1994, management established a restructuring provision of
approximately $3,300,000 to implement an operational restructuring plan
developed to strengthen the Company's competitive position. The plan encompasses
the consolidation or closure of certain centers, adjustments to certain
professional and technical contractual arrangements, changes to the equipment
complement and/or service offerings of certain centers, and legal and settlement
costs.
[10] Stock Options and Warrants
[A] Stock Options - An incentive stock option plan, which was adopted by the
Company and approved by the shareholders, in November of 1992, reserves
2,000,000 shares of the Company's common stock. Options granted under the plan
are intended to qualify as incentive stock options under existing tax
regulations.
In addition, the Company has issued non-qualified stock options from time to
time in connection with acquisitions and for other purposes.
The following table summarizes the activity in common shares subject to
incentive stock options and non-qualified options for the two years ended
October 31, 1995:
Option Price Shares
[Thousands]
November 1, 1993 - Balance .. $ 3.50 - $12.00 9,804
Granted .................. $ 2.50 200
Exercised ................ -- --
Canceled or Expired ...... $ 3.50 - $12.00 4,812
------------- -----
October 31, 1994 - Balance .. $ 2.50 - $12.00 5,192
Granted .................. $ .125 800
Exercised ................ -- --
Canceled or Expired ...... $ .125 - $12.00 3,256
------------- -----
October 31, 1995 - Balance $ .125 - $12.00 2,736
- ============= =====
[B] Warrants - At October 31, 1995 and 1994, there were 4,883,901 warrants
outstanding to acquire the Company's common stock at $3.50 and $7.43 per share,
which expire in June 1997 and January 1998.
[11] Long-Term Debt and Capital Leases
Long-term debt at October 31, 1995 and 1994 consisted of the following:
<TABLE>
<CAPTION>
1 9 9 5 1 9 9 4
------- -------
<S> <C> <C>
Revolving lines of credits, one due December 31, 1998 at the bank's prime rate
plus 4% [minimum 10%], one due December 31, 1997 at the bank's prime rate
plus 4-1/2%. Both lines are collateralized by substantially all of the
Company's assets including
a first position in substantially all of the accounts receivable. $ 5,977,575 $ 4,193,508
Notes payable fixed at 7% to 15%, due through July 2002,
collateralized by medical equipment. 11,871,149 14,005,880
Note payable bearing interest at 9.25% and 12%, due in 2005
and 1998, respectively, secured by real estate. 2,085,175 2,094,075
--------------- ----------------
Totals - Forward $ 19,933,899 $ 20,293,463
</TABLE>
F-16
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #9
- -------------------------------------------------------------------------------
[11] Long-Term Debt and Capital Leases [Continued]
<TABLE>
<CAPTION>
1 9 9 5 1 9 9 4
------- -------
<S> <C> <C>
Totals - Forwarded $ 19,933,899 $ 20,293,463
Notes payable, at 8% and 7%, due through 1999 and 1995,
respectively. Secured by Joint Venture accounts receivable. 1,077,242 1,471,243
Obligation from the Tower Acquisition 8,449,861 9,085,000
Obligations under capital leases, collateralized by medical equipment and office
equipment originally costing approximately $15,400,000 and $17,000,000,
respectively, payable in various monthly installments including interest at
various rates from 6% to 19% through 2002. 14,845,514 18,684,149
Note Payable - Stockholder [See Note 19]. -- 2,500,000
--------------- ----------------
Totals 44,306,516 52,033,855
Less: Current Portion 17,565,435 17,371,927
--------------- ----------------
Totals $ 26,741,081 $ 34,661,928
------ ============= ================
</TABLE>
Under one of the revolving line of credit agreements, due December 31, 1998, the
Company may borrow the lesser of 75% to 80% of eligible accounts receivable,
$7,000,000 or the prior 120 days' cash collections. This credit line is
additionally collateralized by a $5,000,000 life insurance policy on a
shareholder. At October 31, 1995, by formula, the Company had approximately
$712,000 in available credit under this line of credit. The prime rate at
October 31, 1995 and 1994 was 8.75% and 7.75%, respectively; the rate per the
agreement is prime plus 4%, with a minimum of 10%, which amount was reduced to
prime plus 3% subsequent to the year end. Under the second revolving line of
credit agreement due December 31, 1997, the Company may borrow the lesser of 75%
of the eligible accounts receivable, $4,000,000 or the prior 120 days' cash
collection. This credit line is collateralized by approximately 80% of Tower's
accounts receivable. At October 31, 1995, the Company had approximately $483,000
in available credit under this line of credit. The prime rate under this line of
credit was 8.75% at October 31, 1995. Subsequent to year end, the rate on this
loan was reduced from prime plus 4 1/2% to prime plus 3 1/2%.
Principal payments under the obligation from the Tower Acquisition is payable
monthly at the rate of 8% of the cash receipts from centers which are managed by
the Company under the Tower management agreement plus interest at 5%. The rate
of principal payment was increased from 6.9% of cash receipts in February of
1996.
In January of 1996, the Company entered into a third line of credit for the
lesser of 80% of the eligible accounts receivable of FDI, $1,000,000 or the
prior 60 days collections of this subsidiary.
Terms of a capital lease financing agreement require PHS to limit amounts it can
receive from Radnet.
Buy out provisions range from a dollar to fair market value.
In July of 1995, the Company suspended making payments on notes totaling
$5,158,031 and is technically in default on the debt. The Company is currently
negotiating for a reduction and/or extension of the amount due. The entire
amount is classified as a current liability.
F-17
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #10
- -------------------------------------------------------------------------------
[11] Long-Term Debt and Capital Leases [Continued]
The following schedule shows the future maturities of long-term debt exclusive
of capital leases:
Years ended
October 31,
1996 $14,310,340
1997 2,869,913
1998 2,970,039
1999 3,035,526
2000 1,902,046
Thereafter 4,373,138
-----------
Total $29,461,002
------ ===========
The Company leases property under capital leases. The following schedule shows
the minimum lease payments under capital leases as of October 31, 1995:
Years ended
October 31,
1996 $ 4,700,563
1997 4,030,391
1998 3,939,138
1999 2,952,456
2000 1,151,996
Thereafter 2,107,422
-------------------
Total 18,881,966
Less: Amount Representing Interest 4,036,452
Total $ 14,845,514
----- ===================
[12] Commitments and Contingencies
[A] Leases - The Company and its subsidiaries have noncancellable operating
leases for use of their facilities and certain medical equipment. The leases
require payment of various expenses as additional rent and expire at various
times through 2003. Certain leases contain renewal options and escalation
clauses. Minimum annual rentals under the leases are as follows:
Total Equipment Facilities
October 31,
1996 $ 4,777,132 $ 428,210 $ 4,348,922
1997 3,852,349 276,403 3,575,946
1998 3,584,434 75,500 3,508,934
1999 2,790,403 16,275 2,774,128
2000 1,618,384 -- 1,618,384
Thereafter 2,409,618 -- 2,409,618
---------------- ---------------- -----------------
Total $ 19,032,320 $ 796,388 $ 18,235,932
----- ================ ================ =================
F-18
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #11
- ------------------------------------------------------------------------------
[12] Commitments and Contingencies [Continued]
[A] Leases [Continued] - Total rent expense, including equipment rentals, for
the years ended October 31, 1995 and 1994 amounted to approximately $4,500,000
and $3,900,000, respectively.
[B] Salary and Consulting Contractor Agreements - The Company has a variety of
arrangements for payment of professional and employment services. The agreements
provide for the payment of professional fees to physicians under various
arrangements including a percentage of revenue collected from 15% to 20%, fixed
amounts per periods, and combinations thereof.
The Company also has employment agreements with officers and key employees at
annual compensation rates ranging from $100,000 to $275,000 and for periods
extending up to six years. Total commitments under the agreements are
approximately $4,600,000 as of October 31, 1995.
[C] Other - The Company has committed to expenditures of approximately
$1,250,000 over the next year to develop a centralized scheduling,
transcription, billing and collection system. A major supplier of equipment has
agreed to provide financing for substantially all of the project.
The Company has guaranteed the salary payments under an employment contract of
an employee of Care Advantage, Inc. [See Note 21]. Total payments under the
contract as negotiated are $625,000.
[13] Litigation
At November 1, 1993, the Company was a defendant in a putative class action
pending in the United States District Court for the District of New Jersey. In
March 1994, the court denied the plaintiffs' initial motion for class
certification. The plaintiffs subsequently amended the Consolidated Class Action
Complaint and in July 1994, filed a Second Amended and Consolidated Class Action
Complaint in the matter. In the Second Consolidated Complaint, the plaintiffs
named as defendants, the Company, the Company's former principal stockholder, an
entity allegedly controlled by the former principal stockholder, the underwriter
of the Company's December 1992 and June 1993 public offering, a broker dealer
and its President, and another publicly owned corporation.
In the Second Consolidated Complaint, the plaintiffs identified certain alleged
"control" companies and alleged that the defendants violated the federal
securities laws and the Racketeer Influenced Corrupt Organizations ["RICO"] Act
by initiating and/or joining in a conspiracy to manipulate and inflate the
market prices of the "control" companies. The Second Consolidated Complaint
claims damages as well as punitive damages [including treble damages under
"RICO"], interest, attorneys' fees and costs, all of which are unspecified in
amount. In September of 1994, the court certified the matter as a class action.
Four of the defendants have subsequently filed for protection from creditors
pursuant to the federal bankruptcy laws.
Management contends that the Company was not a party to any conspiracy and did
not engage in any illegal course of conduct. Management believes that the Second
Consolidated Complaint is without merit with regard to the Company and intends
to contest it vigorously. However, as the proceeding is currently in the early
discovery stage, management is unable to evaluate the likelihood of an
unfavorable outcome or to estimate the amount or range of any potential loss.
F-19
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #12
- -------------------------------------------------------------------------------
[13] Litigation [Continued]
In March 1993, management of the Company's Primedex subsidiary was made aware of
the prior issuance of a subpoena by a federal grand jury in Los Angeles to
obtain certain records of Primedex in conjunction with a federal investigation
of an unrelated company. Subsequently, the Company was advised of accusations of
alleged health care fraud against the subsidiary which are being investigated in
the federal investigation in response to complaints made by undisclosed third
parties. In December of 1992, a number of Primedex locations, as well as at
least 40 locations of other worker's compensation healthcare providers, were
searched by representatives of the Los Angeles District Attorney's office in
connection with an investigation of an advertising service previously used by
Primedex's affiliated entities and the other providers concerning possible
violations of California law in connection with referral of patients. In June of
1994, additional searches of the premises of the Company and its Primedex and
Radnet subsidiaries were conducted by representatives of the Los Angeles
District Attorney's office pursuant to a sealed affidavit which management has
been unable to examine, alleging violations of California penal laws concerning
securities and tax fraud, grand theft and criminal conspiracy. Management
believes that Primedex's operations have been and are in compliance with
applicable law, is unaware of any illegal activities of the Company or its
subsidiaries and is fully cooperating with the Los Angeles District Attorney's
office in connection with its investigation.
In connection with its cessation of operations at certain of its imaging
centers, lawsuits have been filed against Radnet by the lessors of the
properties for past due rent, future rent and damage to the premises plus costs.
The monthly rent through the lease expiration dates totals approximately
$2,200,000. Radnet has asserted certain defenses in the lawsuits and has accrued
approximately $1,300,000 for past due rent.
In October 1995, the Company and Radnet were sued in a Cross-Complaint by a
number of individuals and entities led by Medical Imaging Center of Los Angeles
["MICLA"]. The litigation relates to an imaging center which was closed in late
1994 [See Note 2]. MICLA was one of the two limited partners of the entity which
owned the center. In late 1994, due to changes in the California Workers'
Compensation system and the adverse impact of these changes upon the centers
facility's business, a decision was made to close the facility. Since that time,
a dispute has arisen among the parties concerning the payment of the liabilities
of the operation. The major lender and equipment lessor for the facility brought
a lawsuit against MICLA and others, not including Radnet or the Company. MICLA
and others named as defendants filed a Cross-Complaint against the Company and
Radnet which seeks damages in an amount which is presently unascertainable but
which is in excess of $1,000,000, punitive damages and treble damages. The
lawsuits is in the discovery phase. Radnet and the Company will continue to
vigorously defend against the claims raised in this lawsuit, and have filed a
Counter-Claim against MICLA and others seeking, among other remedies, the
rescission of the transaction in which the Company acquired its interest in the
entity which operated the imaging center. No assurances or predictions can be
given at this time regarding the probable outcome of this litigation.
The Company is currently a party to certain other litigation, none of which is
deemed material in nature.
[14] Investment in VMI
In November of 1990, the Company purchased 51% of Viromedics, Inc. ["VMI"] for
$700,000. On February 18, 1992, Future Medical Products, the parent of VMI,
exercised its right to repurchase one-half of the stock from PHS at a price of
$700,000, after which the Company owned 25.5% of VMI's outstanding capital
stock. During fiscal 1992, the Company wrote-off its investment in VMI as
research and development costs. At October 31, 1995, PHS owns 19% of VMI, which
is valued at $-0-.
F-20
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #13
- --------------------------------------------------------------------------------
[15] Capital Transactions
[A] As of October 31, 1994, the former principal stockholder was the owner of
10,300,000 shares which represented approximately 26% of the outstanding shares
of the Company for the year. During the year ended October 31, 1995, this
stockholder sold 10,000,000 of his shares to a principal stockholder who is also
an officer and a director of the Company.
[B] On November 17, 1992, the Company increased the number of authorized shares
of common stock, $.01 par value, from 50,000,000 to 100,000,000 shares.
[C] As of January 21, 1993, the Company sold 7,589,010 shares of common stock in
a public offering for net proceeds of $30,493,525 after underwriting discounts
and commissions. In connection with this public offering, the underwriter
received warrants to purchase 758,901 shares of common stock at $7.43 per share.
Substantially all of the offering proceeds were utilized to retire $30,000,000
of bank debt from the Primedex acquisition.
[D] During fiscal 1995, debentures totaling $34,000 were converted into 4,250
shares of common stock.
[F] In October of 1995, the Company sold 200,000 shares at $.01 per share to two
officers of the Company. In connection with the sale, compensation of $18,000
was recorded.
[G] Subsequent to the year end, the Company purchased 1,050,000 shares of its
common stock for an aggregate purchase price of $337,722.
[16] Loss Per Share
Net loss per share is based on the weighted average number of shares of common
stock outstanding during each period of 40,031,461, 40,026,510 and 38,260,311
for fiscal 1995, 1994 and 1993, respectively. No dual presentation of loss per
share is presented because inclusion of common stock equivalents would be
antidilutive.
[17] New Authoritative Pronouncements
The Financial Accounting Standards Board ["FASB"] issued Statement of Financial
Accounting Standards ["SFAS"] No. 123, "Accounting for Stock-Based
Compensation," in October 1995. SFAS No. 123 uses a fair value based method of
accounting for stock options and similar equity instruments as contrasted to the
intrinsic valued based method of accounting prescribed by Accounting Principles
Board [APB] Opinion No. 25, "Accounting for Stock Issued to Employees." The
Company has not decided if it will adopt SFAS No. 123 or continue to apply APB
Opinion No. 25 for financial reporting purposes. SFAS No. 123 will have to be
adopted for financial statement note disclosure purposes in any event. The
accounting requirements of SFAS No. 123, if adopted by the Company, will be
effective for transactions entered into in fiscal years that begin after
December 15, 1995; the disclosure requirements of SFAS No. 123 are effective for
financial statements for fiscal years beginning after December 15, 1995.
On December 30, 1994, the American Institute of Certified Public Accountants
issued Statement of Position [SOP] 94-6, "Disclosure of Certain Significant
Risks and Uncertainties," the provisions of which are effective for financial
statements issued for fiscal years ending after December 15, 1995. In general,
SOP 94-6 requires disclosures about the nature of a company's operations and the
use of estimates in the preparation of financial statements. The Company does
not anticipate a significant expansion of its financial statement note
disclosure as a result of SOP 94-6.
F-21
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #14
- -------------------------------------------------------------------------------
[18] Subordinated Debenture Offering
In June of 1993, the Company's registration statement for a total of
$25,875,000, for 10% Series A Convertible subordinated debentures due 2003 was
declared effective by the Securities and Exchange Commission. The net proceeds
to the Company were approximately $23,000,000. Costs of $2,800,000 are being
amortized over ten years and are classified as other assets. The amortization
expense for fiscal 1995, 1994 and 1993 was approximately $298,495, $298,545 and
$122,708, respectively. Interest expense for fiscal 1995, 1994 and 1993 was
$2,584,100, $2,587,500 and $898,435, respectively.
During fiscal 1995, debentures totaling $34,000 were converted into 4,250 shares
of common stock.
[19] Notes Payable - Stockholders
On January 28, 1993, the Company's four principal shareholders agreed to lend an
aggregate $12,500,000 to the Company for working capital purposes in
consideration for secured notes issued, either directly, for cash, for the
release of debt obligations owed to the Company in connection with the Radnet
acquisition [See Note 7] or for the application of funds escrowed in connection
with the Primedex acquisition.
Each secured note was due in eighteen months with interest at 10%. In July of
1994, one shareholder was paid $3,500,000 and agreed to accept the $4,000,000
balance in twelve equal installments, plus interest at 10%. In August of 1994,
this shareholder accepted a $3,000,000 lump sum payment in full settlement of
the balance. The difference of $1,000,000 was credited to paid-in-capital. In
consideration of this agreement, the other three noteholders agreed to defer
amounts due them on similar terms. Two shareholders who were owed a total of
$2,500,000, agreed to offset this liability against monies owed by them to
Radnet [See Note 7]. In November of 1994, the fourth shareholder, who was owed
$2,500,000 and who had a contingent right to receive an additional $2,500,000
held in escrow in connection with the Primedex acquisition, entered into an
agreement with the Company whereby his liability was satisfied by a payment to
him of $500,000, and the release of the $2,500,000 held in escrow. The
difference of $2,000,000 was credited to accrued estimated closing costs and
subsequently written off in connection with the sale of Primedex [Note 20].
Interest expense relating to these notes for fiscal 1995, 1994 and 1993 was
$-0-, $1,033,000 and $931,000, respectively.
[20] Discontinued Operations - Primedex
On July 29, 1993, the Company commenced its plans to restructure its Primedex
subsidiary and to wind down its involvement in the California worker's
compensation industry.
Effective July 31, 1995, the Company sold substantially all of the assets of
Primedex to an unrelated party for approximately $9,448,000 cash resulting in a
loss of $3,813,314. The assets of Primedex which were sold consisted primarily
of net accounts receivable of $22,087,072 and net property and equipment of
$605,138. Accrued estimated closing costs of $9,100,000 were written-off in
connection with the sale.
The accrued estimated closing costs as of October 31, 1995 and 1994, which are
estimated through the final disposition date of the Primedex subsidiary, consist
of the following:
1 9 9 5 1 9 9 4
------- -------
Salaries and Consultants $ -- $ 5,000,000
Interest -- 1,900,000
Depreciation -- 700,000
Rent and Occupancy Costs 275,000 1,500,000
Other Expenses 450,000 3,011,000
--------------- ----------------
Total $ 731,000 $ 12,111,000
----- =============== ================
F-22
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #15
- -------------------------------------------------------------------------------
[20] Discontinued Operations - Primedex [Continued]
The Company allocated interest to discontinued operations based on debt that was
identified as specifically attributed to those operations.
The amounts allocated are as follows:
<TABLE>
<CAPTION>
Year ended
October 31,
1 9 9 3
<S> <C>
1. Pre-Measurement date income or loss from discontinued operations $ 149,129
==================
2. Post-Measurement date estimated loss on disposal $ 3,570,870
==================
</TABLE>
The operating loss for the Primedex subsidiary prior to July 29, 1993, the
measurement date, of $141,019 is shown separately in the accompanying income
statement. Net revenues of the Primedex subsidiary for the year ended October
31, 1993 were approximately $25,000,000. These amounts are not included in the
net revenues in the accompanying statements of operations.
Discontinued operations on the statement of operations are shown net of the
following tax expense [benefit]:
<TABLE>
<CAPTION>
Y e a r s e n d e d
O c t o b e r 3 1,
1 9 9 5 1 9 9 4 1 9 9 3
------- ------- -------
<S> <C> <C> <C>
Estimated Loss on Discontinued Business
Segment During Phase-out Period $ -- $ -- $ (7,020,000)
================ =============== ================
</TABLE>
[21] Acquisition and Discontinued Operations - Spin-Off of Care Advantage, Inc.
On December 23, 1993, the Company acquired Care Advantage Health Systems
["CAHS"] [formerly known as Advantage Health System, Inc.], a newly organized
corporation formed to provide medical and surgical utilization review for
providers of health insurance. The purchase price was paid for as follows:
$6,000,000 cash, and options exercisable to purchase an aggregate 1,000,000
shares of PHS common stock at an exercise price of $9.00 per share. In August of
1994, Care Advantage, Inc., ["Care Ad"] a wholly-owned subsidiary of PHS, was
incorporated in Delaware as a holding company to own all of the issued and
outstanding common stock of CAHS.
On October 28, 1994, the Company declared a dividend of 40,026,510 shares of the
common stock of CareAd to stockholders of record at the close of business on
November 7, 1994, a rate of one share of Care Advantage common stock for each
share of PHS common stock owned. An additional 1,700,000 shares of Care
Advantage common stock was retained by the Company.
In January of 1995, the Company and CareAd executed a Separation Agreement
concerning additional financial support to be provided by the Company, the
transfer of certain Company senior management, and the disposition of the
1,700,000 shares of CareAd common stock retained by the Company. The separation
agreement was amended on April 24, 1995 [the "Revised Separation Agreement"]. As
part of the Revised Separation Agreement, the Company agreed to a capital
contribution of $9,699,973 of past and future advances. Concerning the 1,700,000
shares of CareAd common stock, the Company agreed to file for a registered
exchange offer under the Securities Act of 1933 with the Securities and Exchange
Commission within eighteen months after the distribution, offering the holders
of the Company's debentures the right to exchange the debentures for the
1,700,000 shares, and possibly other consideration. CareAd has agreed, within
eighteen months after the completion of the exchange offer and subject to
certain conditions, to file a registration statement under the Securities Act of
1933 with the Securities and Exchange Commission registering any of the shares
not distributed, and the Company has agreed to sell such shares. The Company has
agreed that CareAd's Board of Directors will hold all voting rights of the
shares until final disposition.
F-23
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #16
- -------------------------------------------------------------------------------
[21] Acquisition and Discontinued Operations - Spin-Off of Care Advantage, Inc.
[Continued]
Operating results of the discontinued operations of CareAd for fiscal 1994 are:
Gross Revenue $ --
Operating Expenses 3,370,771
---------------
Net [Loss] $ (3,370,771)
---------- ===============
At October 31, 1994, the net assets of CareAd were:
Assets:
Current $ 4,585,149
Property and Equipment - Net 75,340
Goodwill 5,285,714
Other Assets 38,002
---------------
Total 9,984,205
Current Liabilities 551,545
Net Assets $ 9,432,660
---------- ===============
[22] Other Employee Benefit Plans
The Company adopted a profit-sharing/savings plan pursuant to Section 401(k) of
the Internal Revenue Code, whereby eligible employees may contribute on a tax
deferred basis a percentage of compensation, up to the maximum allowable amount
under the tax law, which was $9,240 for 1995. The plan does not require a
matching contribution by the Company. Employee contributions are fully vested
immediately.
[23] Extraordinary Item
During fiscal 1995, the Company settled a note payable with a lump sum payment
that resulted in a $228,485 gain. The Company also restructured debt that
resulted in a $712,399 gain. There was no income tax effect or after-tax effect
on earnings per share on these transactions.
[24] Going Concern
The Company has suffered recurring Losses from operations, has negative working
capital, and has defaulted on certain loans which raises substantial doubt about
its ability to continue as a going concern.
Management has taken the following steps to revise its operating and financial
condition, which it believes are sufficient to provide the Company with the
ability to continue in existence:
In fiscal 1996, the Company expects to increase its net revenues and cash flows
through the November 1995 acquisition of Future Diagnostics, Inc. In addition,
net revenues are expected to increase in the entity's Tower division due to
increased marketing efforts. Cash flows from the Company's Tower accounts
receivable should improve in fiscal 1996 as collections from the receivables
improve.
The Company is presently negotiating with an outside lender to establish new
terms on $5.2 million of debt on which it has defaulted. Management expects to
settle the negotiation on terms favorable to the Company.
The ability of the Company to continue is dependent on the success of these
plans. The financial statements do not include any adjustments that might be
necessary if the Company is unable to continue as a going concern.
. . . . . . . . . . . . .
F-24
<PAGE>
INDEPENDENT AUDITOR'S REPORT ON SUPPLEMENTAL SCHEDULE
To the Stockholders and Board of Directors of
Primedex Health Systems, Inc.
New York, New York
Our report on the consolidated financial statements of
Primedex Health Systems, Inc. and its affiliates is included on page F-1 of this
Form 10-K. In connection with our audits of such financial statements, we have
also audited the related accompanying financial statement Schedule II -Valuation
and Qualifying Accounts.
In our opinion, the financial statement schedule referred to
above, when considered in relation to the basic financial statements taken as a
whole, present fairly, in all material respects, the information required to be
included therein.
MORTENSON AND ASSOCIATES, P. C.
Certified Public Accountants.
Cranford, New Jersey
January 12, 1996
S-1
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- -------------------------------------------------------------------------------
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Additions
Balance at Charged Charged to Deductions Balance at
Beginning Against Other from Close
of Period Income Accounts [A] Reserves of Period
<S> <C> <C> <C> <C> <C>
For the period ended October 31, 1995:
Allowances [Deducted from Accounts
Receivable Short-Term] $ 11,786,427 $ 32,177,329 $ 72,022 $ 28,402,638 $ 15,633,140
============== ============== ============= =============== ==============
Allowances [Deducted from Accounts
Receivable Long-Term] $ 5,051,326 $ 11,361,928 $ 25,431 $ 12,085,583 $ 4,353,102
============== ============== ============= =============== ==============
Amortization of Goodwill [See Note 6] $ 6,947,819 $ 3,851,567 $ -- $ 9,838,388 $ 960,998
============== ============== ============= =============== ==============
Amortization of Other Intangibles
[See Note 6] $ 326,113 $ 193,780 $ -- $ 519,893 $ --
============== ============== ============= =============== ==============
</TABLE>
[A] Addition due to acquisitions.
S-2
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- ------------------------------------------------------------------------------
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
- ------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Additions
Balance at Charged Charged to Deductions Balance at
Beginning Against Other from Close
of Period Income Accounts [A] Reserves of Period
<S> <C> <C> <C> <C> <C>
For the period ended October 31, 1994:
Allowances [Deducted from Accounts
Receivable Short-Term] $ 10,935,736 $ 24,852,187 $ 81,958 $ 24,083,454 $ 11,786,427
============== ============== ============= =============== ==============
Allowances [Deducted from Accounts
Receivable Long-Term] $ 4,650,427 $ 10,650,937 $ 35,125 $ 10,285,163 $ 5,051,326
============== ============== ============= =============== ==============
Amortization of Goodwill [See Note 4] $ 4,361,173 $ 2,608,074 $ -- $ 21,428 $ 6,947,819
============== ============== ============= =============== ==============
Amortization of Other Intangibles
[See Note 4] $ 354,489 $ 243,224 $ -- $ 271,600 $ 326,113
============== ============== ============= =============== ==============
</TABLE>
[A] Addition due to acquisitions.
S-3
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC. AND AFFILIATES
- -------------------------------------------------------------------------------
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
- ------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Additions
Balance at Charged Charged to Deductions Balance at
Beginning Against Other from Close
of Period Income Accounts [A] Reserves of Period
<S> <C> <C> <C> <C> <C>
For the period ended October 31, 1993:
Allowances [Deducted from Accounts
Receivable Short-Term] $ 17,995,278 $ 24,493,903 $ 907,326 $ 32,406,771 $ 10,935,736
============== ============== ============= =============== ==============
Allowances [Deducted from Accounts
Receivable Long-Term] $ 17,609,773 $ 10,474,244 $ 388,854 $ 23,822,444 $ 4,650,427
============== ============== ============= =============== ==============
Amortization of Goodwill [See Note 4] $ 1,550,000 $ 2,811,173 $ -- $ -- $ 4,361,173
============== ============== ============= =============== ==============
Amortization of Other Intangibles
[See Note 4] $ 190,000 $ 220,000 $ -- $ 55,511 $ 354,489
============== ============== ============= =============== ==============
</TABLE>
[A] Addition due to acquisitions.
S-4
<PAGE>
PRIMEDEX HEALTH SYSTEMS, INC.
PART III
Item 10. Directors and Executive Officers of the Registrant
(Information required by Item 10 with respect to directors and
executive officers is incorporated by reference from the Company's proxy
statement to be issued in connection with its 1996 Annual Meeting of
Stockholders or from an amendment on Form 8 to this Report which proxy statement
or amendment will be filed with the Securities and Exchange Commission not later
than 120 days after October 31, 1995.)
Item 11. Executive Compensation
(Information required by Item 11 is incorporated by reference from
the Company's proxy statement to be issued in connection with its 1996 Annual
Meeting of Stockholders or from an amendment on Form 8 to this Report which
proxy statement or amendment will be filed with the Securities and Exchange
Commission not later than 120 days after October 31, 1995.)
Item 12. Security Ownership of Certain
Beneficial Owners and Management
(Information required by Item 12 is incorporated by reference from
the Company's proxy statement to be issued in connection with its 1996 Annual
Meeting of Stockholders or from an amendment on Form 8 to this Report which
proxy statement or amendment will be filed with the Securities and Exchange
Commission not later than 120 days after October 31, 1995.)
Item 13. Certain Relationships and Related Transactions
(Information required by Item 13 is incorporated by reference from
the Company's proxy statement to be issued in connection with its 1996 Annual
Meeting of Stockholders or from an amendment on Form 8 to this Report which
proxy statement or amendment will be filed with the Securities and Exchange
Commission not later than 120 days after October 31, 1995.)
29
<PAGE>
PART IV
Item 14. Exhibits, Financial Statement
Schedules and Reports on Form 8-K
(a) Financial Statements - The following financial statements are
filed herewith:
Page to Page
Independent Auditor's Report......................... F-1
Consolidated Balance Sheets.......................... F-2..F-3
Consolidated Statements of Operations................ F-4..F-5
Consolidated Statements of Stockholders' Equity...... F-6
Consolidated Statements of Cash Flows................ F-7..F-8
Notes to the Consolidated Financial Statements...... F-9..F-24
Schedules - The following financial statement schedules are filed
herewith:
Independent Auditor's Report on Supplemental Information. S-1
Schedule VIII - Valuation and Qualifying Accounts........S-2..S-4
(b) Exhibits - The following exhibits are filed herewith or
incorporated by reference herein:
Incorporated by
Exhibit No. Description of Exhibit Reference to
3.1.1 Certificate of incorporation, (A)
as amended
3.1.2 November 17, 1992 amendment to (A)
the Certificate of Incorporation
3.2 By-laws
4.1 Form of Common Stock (AA)
Certificate
4.2 Form of Indenture between (B)
Registrant and American Stock
Transfer and Trust Company as
Incorporated by Indenture Trustee with
respect to the 10% Series A Convertible
Subordinated Debentures due 2003
4.3 Form of 10% Series A Convertible (B)
Subordinated Debenture Due
2003 (Included in Exhibit 4.2)
30
<PAGE>
Incorporated by
Exhibit No. Description of Exhibit Reference to
10.1 Agreement and Plan of (C)
Reorganization, dated as of
April 30, 1992 by and among
PHS, CCC Franchising Acquisition
Corp. II ("New RadNet"), RadNet
Management, Inc., Beverly Hills
MRI, Dr. Berger and Dr. Krane
10.2 Partnership Purchase (C)
Agreement, dated as of April 30,
1992 by and among PHS, New RadNet
and Dr. Berger and Dr. Krane
10.3 Promissory Note dated June 12, (C)
1992 ("Purchaser Note")
issued by New RadNet in the
principal amount of $10,000,000
payable to Dr. Berger ("Purchaser
Note"). (An identical note
payable to Dr. Krane was issued
to him.)
10.4 PHS Guarantee, dated as of (C)
June 12, 1992, of payment of
the Purchaser Notes
10.5 Stock Pledge Agreement, (C)
dated as of June 12, 1992
pursuant to which PHS as
pledgor pledged the
outstanding capital stock
of New RadNet to Drs.
Berger and Krane to secure
its guarantee
10.6 Secured Promissory Note, (C)
dated June 12, 1992 ("Sellers'
Note") issued by Drs. Berger
and Krane, jointly, in the
principal amount of $6,000,000
payable to New RadNet
10.7 Stock Pledge Agreement (C)
dated as of June 12, 1992
pursuant to which Drs. Berger
and Krane as pledgors pledged
the 5,000,000 shares of PHS
Common Stock issued to them in
the acquisition, to PHS to
secure repayment of the
Sellers' Note
31
<PAGE>
<TABLE>
<CAPTION>
Incorporated by
Exhibit No. Description of Exhibit Reference to
<S> <C>
10.8 Employment Agreement dated as of June 12, (C)
1992 between New RadNet and Howard G.
Berger. (Dr. Krane executed a substantially
identical employment agreement with New
RadNet on said date.)
10.10 Employment Agreement dated as of May 2, (D)
1995 between PHS and Herman Rosenman (to
serve as chief executive officer of New RadNet)
10.11 Asset Purchase Agreement dated as of (D)
October 1, 1994 between the Tower Group and
RadNet Sub
10.12 Management Agreement dated as of (D)
October 1, 1994 between the Tower
Group and RadNet Sub
10.15 Stock Purchase Agreement dated as of (D)
November 9, 1993 for the acquisition of
Advantage Health Systems, Inc. ("AHS")
between PHS, John T. Lincoln and
Paul G. Shoffeitt
10.16 Employment Services Agreement dated (D)
November 9, 1993 between AHS and
Paul G. Shoffeitt (John T. Lincoln executed
a similar employment services agreement with
AHS on the same date)
10.17 Deposit Agreement for stock dividend of CareAd (D)
common stock dated October 31, 1994 among
Midlantic Bank, N.A., PHS and CareAd
10.18 Separation Agreement dated January 31, (D)
1995 between PHS and CareAd
10.19 Separation Agreement dated April 20, (E)
1995 between PHS and CareAd
10.20 Stock Purchase Agreement made as (E)
of June 2, 1995 among PHS, CareAd,
Howard G. Berger and Robert E. Brennan
10.21 Medical Receivable Purchase and Sale Agreement (F)
made as of July 31, 1995 between Bristol A/R and
Primedex Corporation (relating to the sale of the
Primedex Corporation portfolio of workers'
compensation receivables)
</TABLE>
32
<PAGE>
<TABLE>
<CAPTION>
Incorporated by
Exhibit No. Description of Exhibit Reference to
<S> <C>
10.22 Employment Agreement dated as of September 14, *
1995 between PHS and Steven R. Hirschtick
10.23 First Amendment dated September 14, 1995 *
between PHS and Herman Rosenman (consented to
by RadNet), to Employment Agreement dated as of
May 2, 1995 between PHS and Herman Rosenman
10.24 Incentive Stock Option Agreement dated as of *
July 21, 1995 between PHS and Steven R. Hirschtick
10.25 Incentive Stock Option Agreement dated as of *
July 21, 1995 between PHS and Herman Rosenman
10.26 Stock Purchase Agreement dated as of November 14, *
1995 among PHS, RadNet Managed Imaging Services,
Inc. ("RMIS"), Future Diagnostics, Inc. ("FDI")and
the shareholders of FDI relating to the purchaseby
RMIS of all of the outstanding stock of FDI
- -------------
(A) Incorporated by reference to exhibit filed with PHS'
Registration Statement on Form S-1 (File No. 33-51870).
(AA) Incorporated by reference to exhibit filed with PHS'
Registration Statement on Form S-3 File No. 33-73150).
(B) Incorporated by reference to exhibit filed with PHS'
Registration Statement on Form S-3 (File No. 33-59888).
(C) Incorporated by reference to exhibit filed in an amendment
to Form 8-K report for June 12, 1992.
(D) Incorporated by reference to exhibit filed with PHS' annual
report on Form 10-K for the year ended October 31, 1994.
(E) Incorporated by reference to exhibit filed with PHS' Form
8-K report for June 5, 1995. (F) Incorporated by reference to
exhibit filed with PHS' Form 8-K report for August 4,
1995.
(*) To be filed by amendment.
22 Subsidiaries PHS % Ownership State of Incorporation
------------ --------------- ----------------------
Primedex Corporation 100% California
RadNet Management, Inc. 100% California
RadNet Managed Imaging Services,
Inc. 100% California
RadNet Sub, Inc. (a) California
Future Diagnostics, Inc. (b) California
- -----------
(a) Wholly-owned subsidiary of RadNet Management, Inc.
(b) Wholly-owned subsidiary of RadNet Managed Imaging Services,Inc.
PHS also owns approximately 19% of the outstanding common stock of
Viromedics, Inc., a Delaware corporation and approximately 4% of the outstanding
common stock of CareAdvantage, Inc., a Delaware corporation.
(c) Reports on Form 8-K - During the quarter ended October 31, 1995,
PHS did not file any current report on Form 8-K except for a current report on
Form 8-K for August 4, 1995 to report the sale of the portfolio of Workers'
Compensation receivables of its Primedex Corporation subsidiary.
33
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
(Registrant) PRIMEDEX HEALTH SYSTEMS, INC.
Date February 6, 1996 /s/Herman Rosenman
Herman Rosenman, President,
Principal Executive Officer
Date February 6, 1996 /s/Howard G. Berger
---------------- -------------------
Howard G. Berger, Treasurer,
Principal Financial Officer
Date February 6, 1996 /s/John J. Corrigan
---------------- -------------------
John J. Corrigan, Principal
Accounting Officer
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated:
By /s/Howard G. Berger
Howard G. Berger, Director
Date February 6, 1996
By /s/Wilfredo Caraballo
Wilfredo Caraballo, Director
Date February 6, 1996
By /s/Herman Rosenman
Herman Rosenman, Director
Date February 6, 1996
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND THE CONSOLIDATED STATEMENTS OF OPERATIONS AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-END> DEC-31-1995
<CASH> 3,928,832
<SECURITIES> 1,956,707
<RECEIVABLES> 21,664,978
<ALLOWANCES> 43,539,257
<INVENTORY> 0
<CURRENT-ASSETS> 22,553,686
<PP&E> 17,270,032
<DEPRECIATION> 0
<TOTAL-ASSETS> 66,759,704
<CURRENT-LIABILITIES> 26,891,124
<BONDS> 0
0
0
<COMMON> 402,307
<OTHER-SE> (15,242,466)
<TOTAL-LIABILITY-AND-EQUITY> 66,759,704
<SALES> 88,884,136
<TOTAL-REVENUES> 45,344,879
<CGS> 0
<TOTAL-COSTS> 98,124,172
<OTHER-EXPENSES> (5,478,952)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 6,184,302
<INCOME-PRETAX> (58,258,245)
<INCOME-TAX> 0
<INCOME-CONTINUING> (58,556,349)
<DISCONTINUED> (3,813,314)
<EXTRAORDINARY> 940,884
<CHANGES> 0
<NET-INCOME> (61,428,779)
<EPS-PRIMARY> (1.61)
<EPS-DILUTED> (1.61)
</TABLE>
